

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: MICHELSON *et al.*

Appln. No.: To be assigned

Filed: Herewith

For: Systems and Methods for Selecting  
and Recruiting Investigators and  
Subjects for Clinical Studies

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 16602.003

**Preliminary Amendment**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Prior to examination on the merits, Applicants hereby request entry of the following amendments in the above-captioned application:

**In the Specification:**

On page 1, lines 1-2, please replace the title of the application with the following:

SYSTEMS AND METHODS FOR SELECTING AND RECRUITING INVESTIGATORS  
AND SUBJECTS FOR CLINICAL STUDIES

Please delete the paragraph on page 13, beginning on line 16 and ending on 18, and  
replace it with:

Figs. 4A, 4B, 4C and 4D depict an exemplary web page through which a person submits  
one or more disease conditions of interest to a database for identifying eligible subjects for a  
clinical study, in accordance with the present invention.

Please delete the paragraph on page 13, beginning on line 19 and ending on line 20, and  
replace it with:

Figs. 5A through 5J depict an exemplary web page which conveys to a registered user information about clinical studies, in accordance with the present invention.

Please delete the paragraph on page 13, beginning on line 21 and ending on line 23, and replace it with:

Figs. 6A through 6R depict a series of exemplary web pages through which a person can search clinical studies and opt to receive information about clinical studies in one or more selected therapeutic areas, in accordance with the present invention.

Please delete the paragraph on page 14, beginning on line 1 and ending on line 3, and replace it with:

Figs. 7A through 7E depict an exemplary web page that provides a questionnaire that may be completed by an investigator interested in conducting a clinical study, in accordance with the present invention.

Please delete the paragraph page 14, beginning on line 4 and ending on line 5, and replace it with:

Figs. 7F to 7J depict flow diagrams showing processes for registering subjects and investigators, in accordance with alternative embodiments of the present invention.

Please delete the paragraph on page 14, beginning on line 6 and ending on line 7, and replace it with:

Figs. 8A and 8B depict a flow diagram showing the steps performed by a sponsor using the professional site to recruit subjects, investigators, and take steps necessary to start a clinical study.

Please delete the paragraph on page 14, beginning on line 8 and ending on line 9, and replace it with:

Figs. 9A and 9B depict an exemplary web page used by a sponsor to enter study parameters into the system.

Please delete the paragraph on page 14, beginning on line 10 and ending on line 11, and replace it with:

Figs. 10A and 10B depict an exemplary web page used by a sponsor to enter criteria necessary to initiate an investigator search.

Please delete the paragraph on page 14, beginning on lines 18 and ending on line 19, and replace it with:

Figs. 15A through 15H depict an exemplary study-specific subject questionnaire used for prescreening a subject for a clinical study.

Please delete the paragraph on page 15, beginning on line 13 and ending on line 14, and replace it with:

Figs. 22A through 22K depict an exemplary data structure for implementing an investigator database, in accordance with the present invention.

Please delete the paragraph on page 15, beginning on line 15 and ending on line 16, and replace it with:

Figs. 22L-P depict use of a disease incidence search on a TIA database to assist in performing investigator and subject selection, in accordance with the present invention.

Please delete the paragraph on page 15, beginning on line 18 and ending on line 19, and replace it with:

Figs. 24A through 24E depict an exemplary data structure for implementing a subject database, in accordance with the present invention.

Please delete the paragraph on page 15, beginning on line 22 and ending on line 23, and replace it with:

Figs. 26A and 26B depict an exemplary data structure used for implementing the sponsor access limitations shown in Fig. 23.

Please delete the paragraph beginning on page 22, line 13 and ending on page 23, line 10, and replace it with:

Referring still to Figure 1, system 100 also includes an integrated investigator database. In one embodiment, the investigator database includes information from three general sources as described below, although in other embodiments it may include information from a lesser or greater number of sources or different sources. First, the investigator database includes data about the clinical study investigators who wish to inform clinical study sponsors of their clinical study experience and/or training, submitted by the investigators themselves. This self-reported data is typically entered into the investigator database either when a given investigator logs onto the professional site and registers with the system as described further with reference to Figs. 7A through 7E or by submitting such information to the professional site by mail, fax, phone or other non-computerized means. The self-reported data includes various types of information including, for example, the educational background of the investigator, the clinical study experience of the investigator, the past performance of the investigator in other clinical studies (e.g., how many subjects the investigator committed to recruit for a given study and in what period of time, how many subjects the investigator actually recruited for the study and in what period of time, and how many of such subjects actually completed the study), equipment available to the investigator (e.g., whether or not the investigator has access to a CAT scan machine or MRI equipment which may be required for a given study), any mandated IRB

relationships of the investigator (e.g., whether or not the investigator is required through professional affiliations to submit materials to a particular IRB for approval before the materials may be used to advertise the study), any hospital or HMO affiliations of the investigator, information about the investigator's staff and facilities and the geographic location of the investigator.

Please delete the paragraph on page 26, beginning on line 12 and ending on line 21, and replace it with:

Figs. 4A through 4D depict an exemplary web page of subject sites through which a person may submit one or more disease conditions to a database for identifying eligible subjects for a clinical study, in accordance with the present invention. Therapeutic area web page 400 includes pull down menu 401 at which a person may identify a therapeutic area of interest to that person. In this example, the therapeutic area cancer has been chosen. Upon clicking on view button 402, the potential disease conditions of interest are presented to the subject or caregiver in disease condition area 403. The person may check one or more boxes in medical news/drug area 404 or clinical study opportunities area 405 to indicate if the person is interested in obtaining medical news, drug or clinical study opportunity information on any of the disease conditions specified in disease condition area 403.

Please delete the paragraph beginning on page 26, line 22 and ending on page 27, line 4, and replace it with:

Figs. 5A through 5J depict an exemplary web page of the subject site, which conveys information about clinical studies, and provides an ability to search clinical studies to a registered user, in accordance with the present invention. Frequently asked questions area 503 is provided to educate a person on clinical studies. In search area 501, the registered user may

click on any one of the therapeutic areas identified (such as cancer clinical study area 502) and be taken to a search clinical study web page 600, as depicted in Figs. 6A and 6B.

Please delete the paragraph on page 27, beginning on line 12 and ending on line 20, and replace it with:

Upon clicking on contact area 604, the user will be taken to general study interest web page 605 shown in Figs. 6C and 6D. On general study interest web page 605, the registered user may indicate in interest area 606 whether the registered user is interested for himself/herself or for someone else. In one embodiment, the registered user may select in selection area 607 up to three therapeutic areas in which the registered user is interested. In contact area 608, the registered user indicates the manner in which the registered user would like to be contacted, e.g., by e-mail, telephone or regular mail. The registered user also indicates name and contact information in contact information area 609. The registered user submits the form by clicking on submit button 610, or may cancel the process by clicking on cancel button 611.

Please delete the paragraph on page 28, beginning on line 3 and ending on line 16, and replace it with:

In an alternative embodiment, in order to become a user registered with the subject database, the user will be required to provide the information required as shown in the web page depicted in Fig. 6E: a user id; password; password reminder; and whether the user is seeking information for himself or herself or for someone else. In a second step, with reference to Figs. 6F and 6G, the user will be required to provide additional information such as first name, date of birth, gender, electronic mail address, zip code and an indication of one or more medical conditions in which the user is interested. Additional information, though not required for registration, may be provided such as medical conditions experienced by the user, salutation, last

name, ethnic background, telephone number, country of residence, as shown in Fig. 6F. In a third step 3, the user inputs information on a web page such as that shown in Fig. 6H, including a request to receive various types of information (such as, e.g., clinical study opportunities or news and new medical therapies) about the user's medical conditions identified in Figs. 6F and 6G. The user may request that he or she not be sent any information. In area 650, the user is asked to agree to certain terms and conditions governing the user's use of the inventive system.

Please delete the paragraph beginning on page 28, line 17 and ending on page 29, line 3, and replace it with:

Upon completing the required information and accepting the terms and conditions, the user will become a registered user of the inventive system, as shown in the web page depicted in Fig. 6I. At this point, the user may choose to answer additional, optional questions or to return to the previous activity. If the user chooses to answer additional questions, the user may be taken to a web pages such as those depicted in Figs. 6J through 6N and provide information such as the type of prescriptions or over-the-counter medications taken by the user for a given medical condition; the health habits of the user; and the clinical study experience of the user. In Fig. 6O, the user can see if the user has answered completely questions about each medical condition previously listed by the user. In Fig. 6P, the user can provide feedback. In Fig. 6Q, the service provider may provide a thank you to indicate that the message was sent successfully.

Please delete the paragraph on page 29, beginning on line 4 and ending on line 12, and replace it with:

The registered user may also access, on the subject site, the registered user's own personal library. Library web page 612, shown in Fig. 6R, informs the registered user that he or she may maintain a personal library of information relating to clinical studies or new

developments related to particular therapeutic areas found throughout the subject site. The user may also create and save personal notes relating to the same. Information may be placed in the library by the registered user or, in some embodiments, specific information on topics which may be of interest to the registered user may be placed in the registered user's library automatically based on, for example, the registered user's past selections of information to place in the library, therapeutic areas of interest, disease conditions of interest, geographic location, and/or gender.

Please delete the paragraph beginning on page 29 line 14 and ending on page 30, line 6, and replace it with:

An investigator who is interested in conducting clinical studies may express his or her interest by registering on the professional site of Fig. 1B. Figs. 7A, 7B, 7C, 7D, and 7E depict investigator questionnaire web page 700 that provides a questionnaire that may be completed by an investigator interested in conducting a clinical study, in accordance with an embodiment of the present invention. In name area 701, the investigator is required to input his or her name. In degree area 702, the investigator's degree(s) are required. The PRF organization or institutional name, address, city state, country, zip code and telephone number are required (and fax and electronic snail address optionally requested) in contact area 703. Specialty area 704 requires that the investigator provide his or her primary specialty area. Board area 705 requires that the investigator indicate whether he or she is board certified and/or board eligible; optionally, the investigator's year of primary specialty board certification, and board information regarding any of the investigator's subspecialties may be provided. In study experience area 706, the investigator is required to indicate the number of years the investigator has participated in clinical studies as well as all phases of clinical research in which the investigator has

participated. The investigator must include the number of investigators that conduct research at the PRF indicated in investigator area 707.

Please delete the paragraph on page 31, beginning on line 2 and ending on line 9, and replace it with:

Figs. 7F to 7G depict flow diagrams showing processes for registering subjects and investigators, in accordance with alternative embodiments of the present invention. Fig. 7F is directed to persons that register with the subject or investigator site based on a visit to the subject site; Fig. 7G is directed to persons that register with the subject or investigator site based on a contact with a pharmaceutical call center; Figs. 7H and 7J are directed to persons that register with the subject or investigator site based on a contact with an off-line call center and Fig. 7J is directed to persons that register with the subject or investigator site based on a visit to a third party on-line recruitment site.

Please delete the paragraph on page 31, beginning on line 11 and ending on line 15, and replace it with:

Referring now to Figures 8A and 8B, there is shown a flow diagram of a process that may be used by a sponsor to accomplish the steps necessary to start a clinical study. The process may begin at two different points. Specifically, if the sponsor wishes to begin by making a feasibility assessment with respect to the study, the process starts at step 804. Alternatively, if the sponsor does not wish to make a feasibility assessment, the process starts at step 811.

Please delete the paragraph beginning on Page 33, line 15 and ending on page 34, line 8, and replace it with:

The sponsor reaches step 811 either as an entry point into the process, or after the sponsor has determined in step 810 that the study is feasible. In step 811, the sponsor determines

whether the sponsor desires to use the investigator database to perform investigator recruitment for the study. If the sponsor wishes to use the investigator database for investigator recruitment, then in step 815, the sponsor begins by entering study parameter information into the system. A screen shot of a web page that may be used for entering this information is shown in Figures 9A and 9B. In this step, the sponsor enters various parameters about the study into the system.

Next, in step 816, the sponsor enters investigator search criteria for the study into the system. Such search criteria could include, for example, one or more specialties that would be desirable for an investigator for the study, information about the prescribing behavior of the investigator, the number of studies that the investigator has conducted, the therapeutic area and disease indication associated with clinical studies previously conducted by the investigator, the distance around the investigator site in which subjects participating in the study should be sought, and the geographic area in which the investigator should be located. Figures 10A and 10B depict a screen shot of an exemplary web page that may be used by a sponsor to input the investigator search criteria into the system. In step 818, the sponsor is given the ability to weigh one or more of the investigator criteria prior to initiating the investigator search.

Please delete the paragraph beginning on Page 34, line 18 and ending on page 35, line 8, and replace it with:

An exemplary web page that shows the results of an investigator search in accordance with the present invention is shown in Figs. 11A and 11B. As shown in that figure, for each investigator identified in the search, the sponsor is shown the name of the investigator, the investigator's specialty, the city/state in which the investigator is located, the number of studies that the investigator has performed, subject demographic information obtained from the TIA database (i.e. the number of persons listed in the TIA database that are within a predetermined

distance of the investigator site and who could potentially qualify as subjects for the clinical study), subject demographic information obtained from the subject database (i.e. the number of subjects listed in the subject database that are within a predetermined distance of the investigator site and who could potentially qualify to participate in the clinical study), the drug prescribing behavior of the investigator (e.g., the drug class prescribing decile associated with the investigator). It will be understood by those skilled in the art that other criteria relevant to the investigator could also be shown on this search results screen including for example, the behavior of the investigator with respect to ordering of laboratory tests/procedures.

Please delete the paragraph beginning on Page 36, line 22 and ending on page 37, line 19, and replace it with:

After a potential subject has been identified (step 817 or 819), the process of pre-screening for participation in the study begins (step 824). In this step, subjects identified using on-line and/or offline recruitment are notified, and asked whether or not they have an interest in participating in the clinical study. In the case of candidates that were identified on-line using the subject database, the subjects are preferably contacted by the means that they identified during their registration, on the subject site (e.g., by electronic mail) in order to preliminarily determine whether they have an interest in participating in the clinical study. A screen shot of an exemplary e-mail used for providing such a notification to a potential subject is shown in Fig. 14. The notification could alternatively be provided using telephone, mail, fax or any off line communication means. If a potential subject responds to a notification by indicating interest in participating in a clinical study, the subject is provided with a formal questionnaire that asks for information specifically relevant to the clinical study. An exemplary study-specific subject questionnaire is shown in reference to Figs. 15A-15H. In the preferred embodiment, if in

response to the e-mail notification shown in Fig. 14, the subject indicates interest in participating in the clinical study, a study-specific subject questionnaire such as shown in Figs. 15A-15H is provided to the subject on a secure web page found on the subject site. The subject then uses this secure web page to answer all of the questions in the subject questionnaire, and to submit such answers for consideration. As mentioned above, irrespective of whether the subject is ultimately selected for participation in the clinical study, these questionnaire answers are stored in the subject database with the consent of the patient, thereby enriching the subject information stored in that database.

Please delete the paragraph on page 39, beginning on line 2 and ending on 7, and replace it with:

Fig. 16 is a process flow diagram of a method for identifying eligible investigators for a clinical study in accordance with one embodiment of the present invention. Specifically, at step 1610, information is stored in database 2200 of the inventive system (in particular, the data is stored in table 2252, field 2252a of Fig. 22E) relating to the geographic location of each of a plurality of investigators. At step 1620, an incidence or a prevalence of each of a plurality of disease conditions in a plurality of different geographic locations is stored in the database.

Please delete the paragraph on page 46, beginning on line 13 and ending on line 18, and replace it with:

At step 2141, information is stored in the database that associates the types of equipment that an investigator has with one or more disease condition. At step 2142, the database is queried wherein information representing a selected disease condition associated with the specific clinical study is used. The query will result in correspondence between the specific disease

condition and related equipment that an investigator has. At step 2143 the inventive system identifies an investigator based upon the query results and the investigator's equipment.

Please delete the paragraph beginning on Page 46, line 19 and ending on page 47, line 2, and replace it with:

Fig. 21L is a process flow diagram depicting the steps of a method for identifying eligible investigators for a clinical study in accordance with yet a further embodiment of the present invention. At step 2143', information is stored in the inventive system database relating to prospective investigators for clinical studies, which includes the investigator practice setting, which is where the actual clinical study is conducted, and where a subject would most likely go to participate. 'this information is provided by the investigator.

Please delete the paragraph beginning on Page 59, line 15 and ending on page 60 line 2, and replace it with:

Fig. 22A through 22K is an exemplary data structure for implementing an investigator database 2200. For example, table 2210 includes investigator data related to basics such as name, age, address, phone, etc. Table 2220 contains data about a specific study performed by the investigator, Table 2230 relates to the investigator's specialties, and Table 2240 relates to the investigator's subject population. Shown in Figs. 22C and 22E, table 2250 contains data about the investigator's staff. Table 2260 of Fig. 22F contains data regarding the investigator's hospital affiliations. It will be understood by those skilled in the art that the investigator database of the present invention could be implemented using many different formats or structures, and that the particular structure shown in Figs. 22A thorough 22K represents one example of such a data structure.

Please delete the paragraph on page 60, beginning on line 4 and ending on line 20, and replace it with:

Figs. 22L-P depict use of a disease incidence search on a TIA database to assist in performing investigator and subject selection. The example shown relates specifically to use of the invention to perform a study related to the disease of angina. Initially, the TIA database is queried using angina as the query criterion to identify geographic locations where the incidence of angina is more prevalent. These areas are identified on a national basis in Fig. 22L, and specifically for the Dallas-Fort Worth area in Fig. 22M. It bears noting that, within the Dallas-Fort Worth area, the TIA database IMS further identified an incidence value for each sub-region of the Dallas-Fort Worth area. Sites of various investigators in Dallas-Fort Worth that are potentially eligible to perform the study are also shown on Fig. 22M. These investigator sites were found by querying the investigator database as described above. Fig. 22N shows that there are three eligible investigator sites in the Dallas-Fort Worth Area. These three investigator sites are shown as circled stars in Fig. 22N. Of the three eligible investigator sites, one of the investigator sites is located in a sub-region having a higher incidence of angina than is found in the sub-regions of the other two eligible investigators. As shown in Fig. 22O, the investigator located in the sub-region having the highest incidence of angina is next selected to perform the study. Following selection of this investigator for the study, subjects closest to the site of the selected investigator are identified for screening, as shown in Fig. 22P.

Please delete the paragraph on page 61, beginning on line 12 and ending on line 15, and replace it with:

Fig. 23 is a screen shot showing sponsor access limitations to study data. Aggregated data 2302 can be viewed by all sponsors, whereas data 2304 can only be viewed by the sponsor that

supplied that data 2304 to the database. Figs. 26A and 26B depict an exemplary data structure used for implementing the sponsor access limitations discussed above.

**In the Claims:**

Please delete claims 16-120 and add new claims 121-128

Claim 121 (New) A method for recruiting a person to participate as a subject in a clinical study, comprising:

- (a) presenting one or more web pages that allow the person or a caregiver associated with the person to register with a database by submitting registration information to the database;
- (b) registering automatically the person or caregiver with the database upon receipt of the registration information;
- (c) determining automatically in accordance with the registration information whether to provide the person or caregiver with notice of a given clinical study associated with a therapeutic area, disease, or condition of interest to the person; and
- (d) providing the person or caregiver with notice of the given clinical study if a determination is made to provide such notice.

Claim 122 (New) The method as in claim 121, wherein said information comprises a geographic location of the person, a therapeutic area, disease, or condition of interest to the person, contact information, and permission information indicating whether the person or caregiver wishes to receive notice of one or more clinical studies.

Claim 123 (New) A method for recruiting a person to participate as a subject in a clinical study, comprising:

- (a) presenting one or more web pages that allow the person or a caregiver associated with the person to transfer information about the person over the Internet to a database;
- (b) determining automatically in accordance with said information whether to provide the person or caregiver with notice of a given clinical study associated with a therapeutic area, disease, or condition of interest to the person; and
- (c) providing the person or caregiver with notice of the given clinical study if a determination is made to provide such notice.

TOEPPEN 201500

- Claim 124 (New) The method as in claim 123, wherein said information comprises a geographic location of the person, a therapeutic area, disease, or condition of interest to the person, contact information, and permission information indicating whether the person or caregiver wishes to receive notice of one or more clinical studies.
- Claim 125 (New) The method as in claim 123 further comprising registering said information in a database.
- Claim 126 (New) A method for recruiting a person to participate as a subject in a clinical study, comprising the step of presenting one or more web pages that allow the person or a caregiver associated with the person to transfer information about the person over the Internet to a database.
- Claim 127 (New) The method as in claim 126, wherein said information comprises geographic location, zip code of residence, e-mail address, and contact information.
- Claim 128 (New) The method as in claim 126, wherein said information comprises specific information about said person's medical condition, disease status, symptoms, duration of illness, medications taken, and prior treatment options.

**Remarks**

Support for the added claims can be found throughout the specification and in the claims as filed. No new matter enters by this amendment.

Applicants note that 114 sheets of formal drawings are attached to this preliminary amendment for replacement of the informal drawings that were included with the filing of parent application number PCT/US01/02936. Applicants note that the figures have been reformatte in order to comply with 37 C.F.R.. Some numbers and letters in some figure headings have been relabelled in the process. No new matter has thereby been introduced.

Applicants note that a petition to make special also accompanies this amendment and add that if the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to Arnold & Porter Deposit Account No. 50-1824.

Prompt and favorable consideration of the application is respectfully requested.

Respectfully submitted,

Joseph A. Micallef (Reg. No. 39,772)  
Andrew S. Benc (Reg. No. 45,534)

Date: \_\_\_\_\_

ARNOLD & PORTER  
555 12<sup>th</sup> Street, N.W.  
Washington, D.C. 20004  
202.942.5000 telephone  
202.942.5999 facsimile

### **Marked-Up Specification**

On page 1, lines 1-2

SYSTEMS AND METHODS FOR SELECTING AND RECRUITING [INVESTIGATIONS]

INVESTIGATORS AND SUBJECTS FOR CLINICAL STUDIES

On page 13, lines 16-18

Figs. 4A, 4B[ and 4C], 4C and 4D depict an exemplary web page through which a person submits one or more disease conditions of interest to a database for identifying eligible subjects for a clinical study, in accordance with the present invention.

On page 13, lines 19-20

Figs. 5A through [5F] 5J depict an exemplary web page which conveys to a registered user information about clinical studies, in accordance with the present invention.

On page 13, lines 21-23

Figs. 6A through [6N] 6R depict a series of exemplary web pages through which a person can search clinical studies and opt to receive information about clinical studies in one or more selected therapeutic areas, in accordance with the present invention.

On page 14, lines 1-3

Figs. 7A[, 7B 7C] through 7E depict an exemplary web page that provides a questionnaire that may be completed by an investigator interested in conducting a clinical study, in accordance with the present invention.

On page 14, lines 4-5

Figs. [7D to 7G] 7F to 7I depict flow diagrams showing processes for registering subjects and investigators, in accordance with alternative embodiments of the present invention.

On page 14, lines 6-7

TOP SECRET - GOVERNMENT USE ONLY

Figs. 8A and 8B depict [is] a flow diagram showing the steps performed by a sponsor using the professional site to recruit subjects, investigators, and take steps necessary to start a clinical study.

On page 14, lines 8-9

Figs. 9A and 9B depict [is] an exemplary web page used by a sponsor to enter study parameters into the system.

On page 14, lines 10-11

Figs. 10A and 10B depict [is] an exemplary web page used by a sponsor to enter criteria necessary to initiate an investigator search.

On page 14, lines 18-19

Figs. 15A through [15F] 15H depict [is] an exemplary study-specific subject questionnaire used for prescreening a subject for a clinical study.

On page 15, lines 13-14

Figs. 22A through [22F] 22K depict an exemplary data structure for implementing an investigator database, in accordance with the present invention.

On page 15, lines 15-16

Figs. 22[G-K]L-P depict use of a disease incidence search on a TIA database to assist in performing investigator and subject selection, in accordance with the present invention.

On page 15, lines 18-19

Figs. 24A through [24D] 24E depict an exemplary data structure for implementing a subject database, in accordance with the present invention.

On page 15, lines 22-23

Figs. 26A and 26B depict[s] an exemplary data structure used for implementing the sponsor access limitations shown in Fig. 23.

On page 22, line 13 through page 23, line 10

Referring still to Figure 1, system 100 also includes an integrated investigator database.

In one embodiment, the investigator database includes information from three general sources as described below, although in other embodiments it may include information from a lesser or greater number[s] of sources or different sources. First, the investigator database includes data about the clinical study investigators who wish to inform clinical study sponsors of their clinical study experience and/or training, submitted by the investigators themselves. This self-reported data is typically entered into the investigator database either when a given investigator logs onto the professional site[,] and registers with the system as described further with reference to Figs. 7A through [7C] 7E or by submitting such information to the professional site by mail, fax, phone or other non-computerized means. The self-reported data includes various types of information including, for example, the educational background of the investigator, the clinical study experience of the investigator, the past performance of the investigator in other clinical studies (e.g., how many subjects the investigator committed to recruit for a given study and in what period of time, how many subjects the investigator actually recruited for the study and in what period of time, and how many of such subjects actually completed the study), equipment available to the investigator (e.g., whether or not the investigator has access to a CAT scan machine or MRI equipment which may be required for a given study), any mandated IRB relationships of the investigator (e.g., whether or not the investigator is required through professional affiliations to submit materials to a particular IRB for approval before the materials may be used to advertise the study), any hospital or HMO affiliations of the investigator,

information about the investigator's staff and facilities and the geographic location of the investigator.

On page 26, lines 12-21

Figs. 4A through 4[C]D depict an exemplary web page of subject sites through which a person may submit one or more disease conditions to a database for identifying eligible subjects for a clinical study, in accordance with the present invention. Therapeutic area web page 400 includes pull down menu 401 at which a person may identify a therapeutic area of interest to that person. In this example, the therapeutic area cancer has been chosen. Upon clicking on view button 402, the potential disease conditions of interest are presented to the subject or caregiver in disease condition area 403. The person may check one or more boxes in medical news/drug area 404 or clinical study opportunities area 405 to indicate if the person is interested in obtaining medical news, drug or clinical study opportunity information on any of the disease conditions specified in disease condition area 403.

On page 26, line 22 through page 27, line 4

Figs. 5A through 5[F]J depict an exemplary web page of the subject site, which conveys information about clinical studies, and provides an ability to search clinical studies to a registered user, in accordance with the present invention. Frequently asked questions area 503 is provided to educate a person on clinical studies. In search area 501, the registered user may click on any one of the therapeutic areas identified (such as cancer clinical study area 502) and be taken to a search clinical study web page 600, as depicted in Figs. 6A and 6B.

On page 27, lines 12-20,

Upon clicking on contact area 604, the user will be taken to general study interest web page 605 shown in Figs. 6C and 6D. On general study interest web page 605, the registered user

may indicate in interest area 606 whether the registered user is interested for himself/herself or for someone else. In one embodiment, the registered user may select in selection area 607 up to three therapeutic areas in which the registered user is interested. In contact area 608, the registered user indicates the manner in which the registered user would like to be contacted, e.g., by e-mail, telephone or regular mail. The registered user also indicates name and contact information in contact information area 609. The registered user submits the form by clicking on submit button 610, or may cancel the process by clicking on cancel button 611.

On page 28, lines 3-16

In an alternative embodiment, in order to become a user registered with the subject database, the user will be required to provide the information required as shown in the web page depicted in Fig. 6[D]E: a user id; password; password reminder; and whether the user is seeking information for himself or herself or for someone else. In a second step, with reference to Figs. 6[E]F and 6G, the user will be required to provide additional information such as first name, date of birth, gender, electronic mail address, zip code and an indication of one or more medical conditions in which the user is interested. Additional information, though not required for registration, may be provided such as medical conditions experienced by the user, salutation, last name, ethnic background, telephone number, country of residence, as shown in Fig. 6F. In a third step 3, the user inputs information on a web page such as that shown in Fig. 6[F]H, including a request to receive various types of information (such as, e.g., clinical study opportunities or news and new medical therapies) about the user's medical conditions identified in Figs. 6[E]F and 6G. The user may request that he or she not be sent any information. In area 650, the user is asked to agree to certain terms and conditions governing the user's use of the inventive system.

On page 28, line 17 through page 29, line 3

Upon completing the required information and accepting the terms and conditions, the user will become a registered user of the inventive system, as shown in the web page depicted in Fig. 6[G]I. At this point, the user may choose to answer additional, optional questions or to return to the previous activity. If the user chooses to answer additional questions, the user may be taken to a web pages such as those depicted in Figs. 6[H]J through 6[J]N and provide information such as the type of prescriptions or over-the-counter medications taken by the user for a given medical condition; the health habits of the user; and the clinical study experience of the user. In Fig. 6[K]O, the user can see if the user has answered completely questions about each medical condition previously listed by the user. In Fig. 6[L]P, the user can provide feedback. In Fig. 6[M]Q, the service provider may provide a thank you to indicate that the message was sent successfully.

On page 29, lines 4-12

The registered user may also access, on the subject site, the registered user's own personal library. Library web page 612, shown in Fig. 6[N]R, informs the registered user that he or she may maintain a personal library of information relating to clinical studies or new developments related to particular therapeutic areas found throughout the subject site. The user may also create and save personal notes relating to the same. Information may be placed in the library by the registered user or, in some embodiments, specific information on topics which may be of interest to the registered user may be placed in the registered user's library automatically based on, for example, the registered user's past selections of information to place in the library, therapeutic areas of interest, disease conditions of interest, geographic location, and/or gender.

On page 29 line 14 to page 30, line 6

An investigator who is interested in conducting clinical studies may express his or her interest by registering on the professional site of Fig. 1B. Figs. 7A, 7B[ and 7C], 7C, 7D, and 7E depict investigator questionnaire web page 700 that provides a questionnaire that may be completed by an investigator interested in conducting a clinical study, in accordance with an embodiment of the present invention. In name area 701, the investigator is required to input his or her name. In degree area 702, the investigator's degree(s) are required. The PRF organization or institutional name, address, city state, country, zip code and telephone number are required (and fax and electronic snail address optionally requested) in contact area 703. Specialty area 704 requires that the investigator provide his or her primary specialty area. Board area 705 requires that the investigator indicate whether he or she is board certified and/or board eligible; optionally, the investigator's year of primary specialty board certification, and board information regarding any of the investigator's subspecialties may be provided. In study experience area 706, the investigator is required to indicate the number of years the investigator has participated in clinical studies as well as all phases of clinical research in which the investigator has participated. The investigator must include the number of investigators that conduct research at the PRF indicated in investigator area 707.

Page 31, lines 2-9

Figs. [7D to 7G] 7F to 7G depict flow diagrams showing processes for registering subjects and investigators, in accordance with alternative embodiments of the present invention. Fig. 7[D] F is directed to persons that register with the subject or investigator site based on a visit to the subject site; Fig. 7[E] G is directed to persons that register with the subject or investigator site based on a contact with a pharmaceutical call center; [Fig. 7F] Figs. 7H and 7J are [is] directed to persons that register with the subject or investigator site based on a contact with an

off-line call center and Fig. 7[G] I is directed to persons that register with the subject or investigator site based on a visit to a third party on-line recruitment site.

Page 31, lines 11-15

Referring now to [Figure 8] Figures 8A and 8B, there is shown a flow diagram of a process that may be used by a sponsor to accomplish the steps necessary to start a clinical study. The process may begin at two different points. Specifically, if the sponsor wishes to begin by making a feasibility assessment with respect to the study, the process starts at step 804. Alternatively, if the sponsor does not wish to make a feasibility assessment, the process starts at step 811.

Page 33, line 15 to page 34, line 8

The sponsor reaches step 811 either as an entry point into the process, or after the sponsor has determined in step 810 that the study is feasible. In step 811, the sponsor determines whether the sponsor desires to use the investigator database to perform investigator recruitment for the study. If the sponsor wishes to use the investigator database for investigator recruitment, then in step 815, the sponsor begins by entering study parameter information into the system. A screen shot of a web page that may be used for entering this information is shown in [Figure 9] Figures 9A and 9B. In this step, the sponsor enters various parameters about the study into the system. Next, in step 816, the sponsor enters investigator search criteria for the study into the system. Such search criteria could include, for example, one or more specialties that would be desirable for an investigator for the study, information about the prescribing behavior of the investigator, the number of studies that the investigator has conducted, the therapeutic area and disease indication associated with clinical studies previously conducted by the investigator, the distance around the investigator site in which subjects participating in the study should be

sought, and the geographic area in which the investigator should be located. [Figure 10] Figures 10A and 10B depict [is] a screen shot of an exemplary web page that may be used by a sponsor to input the investigator search criteria into the system. In step 818, the sponsor is given the ability to weigh[t] one or more of the investigator criteria prior to initiating the investigator search.

Page 34, line 18 to page 35, line 8

An exemplary web page that shows the results of an investigator search in accordance with the present invention is shown in [Fig. 11] Figs. 11A and 11B. As shown in that figure, for each investigator identified in the search, the sponsor is shown the name of the investigator, the investigator's specialty, the city/state in which the investigator is located, the number of studies that the investigator has performed, subject demographic information obtained from the TIA database (i.e. the number of persons listed in the TIA database that are within a predetermined distance of the investigator site and who could potentially qualify as subjects for the clinical study), subject demographic information obtained from the subject database (i. e., the number of subjects listed in the subject database that are within a predetermined distance of the investigator site and who could potentially qualify to participate in the clinical study), the drug prescribing behavior of the investigator (e.g., the drug class prescribing decile associated with the investigator). It will be understood by those skilled in the art that other criteria relevant to the investigator could also be shown on this search results screen including for example, the behavior of the investigator with respect to ordering of laboratory tests/procedures.

Page 36, line 22 to page 37, line 19

After a potential subject has been identified (step 817 or 819), the process of pre-screening for participation in the study begins (step 824). In this step, subjects *identifies* using

on-line and/or offline recruitment are notified, and asked whether or not they have an interest in participating in the clinical study. In the case of candidates that were identified on-line using the subject database, the subjects are preferably contacted by the means that they identified during their registration, on the subject site (e.g., by electronic mail) in order to preliminarily determine whether they have an interest in participating in the clinical study. A screen shot of an exemplary e-mail used for providing such a notification to a potential subject is shown in Fig. 14. The notification could alternatively be provided using telephone, mail, fax or any off line communication means. If a potential subject responds to a notification by indicating interest in participating in a clinical study, the subject is provided with a formal questionnaire that asks for information specifically relevant to the clinical study. An exemplary study-specific subject questionnaire is shown in reference to Figs. 15A – 15[F] H. In the preferred embodiment, if in response to the e-mail notification shown in Fig. 14, the subject indicates interest in participating in the clinical study, a study-specific subject questionnaire such as shown in Figs. 15A- 15[F] H is provided to the subject on a secure web page found on the subject site. The subject then uses this secure web page to answer all of the questions in the subject questionnaire, and to submit such answers for consideration. As mentioned above, irrespective of whether the subject is ultimately selected for participation in the clinical study, these questionnaire answers are stored in the subject database with the consent of the patient, thereby enriching the subject information stored in that database.

Page 39 lines 2-7

Fig. 16 is a process flow diagram of a method for identifying eligible investigators for a clinical study in accordance with one embodiment of the present invention. Specifically, at step 1610, information is stored in database 2200 of the inventive system (in particular, the data is

stored in table 2252, field 2252a of Fig. 22[B] E) relating to the geographic location of each of a plurality of investigators. At step 1620, an incidence or a prevalence of each of a plurality of disease conditions in a plurality of different geographic locations is stored in the database.

Page 46 lines 13-18

At step [2140] 2141, information is stored in the database that associates the types of equipment that an investigator has with one or more disease condition[s]. At step [2141] 2142, the database is queried wherein information representing a selected disease condition associated with the specific clinical study is used. The query will result in correspondence between the specific disease condition and related equipment that an investigator has. At step [2142] 2143 the inventive system identifies an investigator based upon the query results and the investigator's equipment.

Page 46 line 19 to page 47, line 2

Fig. 21L is a process flow diagram depicting the steps of a method for identifying eligible investigators for a clinical study in accordance with yet a further embodiment of the present invention. At step 2143', information is stored in the inventive system database relating to prospective investigators for clinical studies, which includes the investigator practice setting, which is where the actual clinical study is conducted, and where a subject would most likely go to participate. 'this information is provided by the investigator.

Page 59, line 15 to page 60 line 2

Fig. 22A through 22[F] K is an exemplary data structure for implementing an investigator database 2200. For example, table 2210 includes investigator data related to basics such as name, age, address, phone, etc. Table 2220 contains data about a specific study performed by the investigator, Table 2230 relates to the investigator's specialties, and Table 2240 relates to the

investigator's subject population. Shown in [Fig. 22B] Figs. 22C and 22E, table 2250 contains data about the investigator's staff. Table 2260 of Fig. 22[C] E contains data regarding the investigator's hospital affiliations. It will be understood by those skilled in the art that the investigator database of the present invention could be implemented using many different formats or structures, and that the particular structure shown in Figs. 22A thorough 22[F] K represents one example of such a data structure.

Page 60, lines 4-20

Figs. 22[G-K] L-P depict use of a disease incidence search on a TIA database to assist in performing investigator and subject selection. The example shown relates specifically to use of the invention to perform a study related to the disease of angina. Initially, the TIA database is queried using angina as the query criterion to identify geographic locations where the incidence of angina is more prevalent. These areas are identified on a national basis in Fig. 22[G] L, and specifically for the Dallas-Fort Worth area in Fig. 22[H] M. It bears noting that, within the Dallas-Fort Worth area, the TIA database IMS further identified an incidence value for each sub-region of the Dallas-Fort Worth area. Sites of various investigators in Dallas-Fort Worth that are potentially eligible to perform the study are also shown on Fig. 22[H] M. These investigator sites were found by querying the investigator database as described above. Fig. 22[1] N shows that there are three eligible investigator sites in the Dallas-Fort Worth Area. These three investigator sites are shown as circled stars in Fig. 22[1] N. Of the three eligible investigator sites, one of the investigator sites is located in a sub-region having a higher incidence of angina than is found in the sub-regions of the other two eligible investigators. As shown in Fig. 22[J] Q, the investigator located in the sub-region having the highest incidence of angina is next selected to perform the study. Following selection of this investigator for the

study, subjects closest to the site of the selected investigator are identified for screening, as shown in Fig. 22[K] P.

Page 61, lines 12-15

Fig. 23 is a screen shot showing sponsor access limitations to study data. Aggregated data 2302 can be viewed by all sponsors, whereas data 2304 can only be viewed by the sponsor that supplied that data 2304 to the database. [Fig. 26] Figs. 26A and 26B depict[s] an exemplary data structure used for implementing the sponsor access limitations discussed above.





FIG. 1A

## APPLICATION ARCHITECTURE 100



<input type="text" value="Search"/> <input type="button" value="go"/>	<input type="text" value="Search clinical trials"/> <input type="button" value="go"/>
<h3>Register</h3> <p>To register to become a member, just fill in the form below.</p>	
<input type="text" value="Email"/> <span style="margin-left: 20px;">200</span>	<input type="text" value="Username"/> <span style="margin-left: 20px;">200</span>
<input type="text" value="Password"/> <span style="margin-left: 20px;">200</span>	<input type="text" value="Retype Password"/> <span style="margin-left: 20px;">200</span>
<p>Your privacy is of the utmost concern to us. For more information, read <a href="#">Privacy &amp; Security Policy.</a> <span style="margin-left: 20px;">204</span></p>	
<p>As part of the registration process and to protect your privacy, we ask that you please choose one of the questions in the box below and type the answer into the second box. If you forget your password, this question will be given to you. After correctly answering the question, you will be asked to reset your password so you can have full access to the site.</p>	
<p>Your question <span style="border: 1px solid black; padding: 2px;">What is your mother's maiden name ?</span> <span style="margin-left: 20px;">204</span></p>	
<p> <input type="radio"/> Register Now  <input type="radio"/> Review Clinical Trials Ask Questions and More         </p>	

FIG. 2A

205 Your answer, up to 45 characters.

	△
	▽

### Terms of Service

Please read the following Terms of Service agreement.

Terms of Service Agreement	△
	▽

206

I Agree

I Do Not Agree

### Benefits of Registration

Registered users will benefit from:

- Our comprehensive clinical trial listings - get trial information and find out how you can be considered for participation in clinical trials.
- The ability to ask questions of our medical experts.
- Timely, relevant announcements of new trials and drug information.
- Exclusive interactive tools, including your own personal library of news information.
- Emails informing you of updates to our clinical trial listings, news and information, tailored to your selection.
- A personal profile used to optimize your experience.

FIG. 2B

5/114

Search <input type="text"/>	<input type="button" value="go"/>	Home / <input type="button" value="go"/>	Search clinical trials <input type="button" value="go"/>	300																		
<p><b>Personal Information</b></p> <p>Add or modify your name, password, address and other information about you.</p> <table border="1"> <tr> <td>First Name</td> <td>301</td> </tr> <tr> <td>Last Name</td> <td>301</td> </tr> <tr> <td>Phone #</td> <td>ext. <input type="text"/></td> </tr> <tr> <td>Address</td> <td>301</td> </tr> <tr> <td>City</td> <td>301</td> </tr> <tr> <td>State</td> <td>Select <input type="button" value="▼"/></td> </tr> <tr> <td>ZIP CODE</td> <td>301</td> </tr> <tr> <td>Email</td> <td>301</td> </tr> <tr> <td>Gender</td> <td><input type="radio"/> Male   <input checked="" type="radio"/> Female</td> </tr> </table> <p><input type="radio"/> Change My Password  <input type="radio"/> Change My Question</p> <p><input type="radio"/> Show My Library welcome page   <input checked="" type="radio"/> Yes   <input type="radio"/> No  <input type="radio"/> Show My Profile welcome page   <input checked="" type="radio"/> Yes   <input type="radio"/> No</p> <p><input type="radio"/> Save</p>					First Name	301	Last Name	301	Phone #	ext. <input type="text"/>	Address	301	City	301	State	Select <input type="button" value="▼"/>	ZIP CODE	301	Email	301	Gender	<input type="radio"/> Male <input checked="" type="radio"/> Female
First Name	301																					
Last Name	301																					
Phone #	ext. <input type="text"/>																					
Address	301																					
City	301																					
State	Select <input type="button" value="▼"/>																					
ZIP CODE	301																					
Email	301																					
Gender	<input type="radio"/> Male <input checked="" type="radio"/> Female																					
<p><b>Personal Information</b></p> <p>Medical condition</p> <p>Contacts</p> <p><b>Therapeutic Area</b></p> <p><input type="radio"/> Cancer  <input type="radio"/> Neurological Conditions</p> <p><b>Register Now</b></p> <p><input type="radio"/> Review Clinical Trials Ask Questions and More</p>																						

FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C

□    □□□    □□□□□□□□□□□□

□    □□□    □□□□□□□□□□

Rectal Cancer  
Renal Cell  
Carcinoma  
Sarcoma  
Skin Cancer  
Spinal Cord  
Malignancy  
Stomach Cancer  
T-Cell Lymphoma  
Testicular Cancer  
Thrombocytopenia  
Thymomas  
Vaginal Cancer  
Vulvar Carcinoma  
Wilms' Tumor

FIG. 4D

CLINICAL

Search

Search clinical trials

Home / About Us /

**About Clinical Trials**

Search Clinical Trials

Feature Stories  
 News Archive  
 Ask the Expert  
 About Clinical Trials  
 Tutorial  
 Therapeutic Area  
 Cancer  
 Neurological Conditions

Cancer 502  
 Cardiology/Vascular Diseases  
 Dental/Maxillofacial Surgery  
 Dermatology/Plastic Surgery  
 Endocrinology  
 Gastroenterology  
 Hematology  
 Immunology/Infectious Diseases  
 Musculoskeletal  
 Nephrology/Urology

Neurological Conditions 501  
 Obstetrics/Gynecology  
 Ophthalmology  
 Otolaryngology  
 Pediatrics/Neonatology  
 Pharmacology/Toxicology  
 Pulmonary/Respiratory Diseases  
 Rheumatology  
 Trauma/Emergency Medicine

Clinical Trials FAQ

Introduction: What are clinical trials?  
 Why are clinical trials important?  
 The clinical trial process  
 How are participant's rights and safety protected during a clinical trial?  
 Who pays for clinical trials?  
 Where can you get more information about clinical trials?  
 Questions you need to ask.  
 Common terms used in clinical trials.

**Register Now**  
Review Clinical Trials Ask Questions and More

FIG. 5A

Quite simply, a clinical trial is a very carefully structured study that evaluates the effectiveness of a drug against a specific disease or condition. Clinical trials can focus on a new drug or they may be used to determine new uses for existing medications.

When a promising new medication is identified, the drug undergoes careful evaluation for safety and effectiveness through the clinical trial process. Typically, the doctors chosen to conduct clinical trials are experts within their medical specialties. The pharmaceutical or biotechnology company that is sponsoring the trial reports their findings to the U.S. Food and Drug Administration (FDA). The FDA reviews those findings and if they determine that the drug is both effective and safe to use, then they will make the drug available for broader use by doctors and their patients.

Doctors conducting clinical trials frequently ask their patients if they are interested in volunteering to participate in a clinical trial. Each trial has different requirements for how it is conducted, such as conditions for patient eligibility, length of the study, dosage of the study drug, and types of medical procedures, to name a few. If you are interested in participating in a clinical trial, it is very important that you review these requirements with the doctor conducting the clinical trial to ensure your eligibility and to determine the potential benefits and risks from the trial.

FIG. 5B

If you are looking for clinical trials that may be beneficial for you, please search our clinical trials listing for details on type and location. This is the first step to review the exciting medical research on the potential new treatments of tomorrow that may benefit you today.

© Back to top

503

### Why are clinical trials important ?

Clinical trials are important to increase medical knowledge and find better ways to help people. Generally, the goal of clinical trials is to introduce an investigational treatment that is safer and more effective than the standard treatment for a particular disease or condition. In addition, for those diseases for which there are no treatment options, research and clinical trials may be the only avenue to uncover a potential treatment.

© Back to top

### The clinical trial process.

After a drug is successfully tested in laboratory and animal studies, the FDA grants approval for testing to begin in humans. The testing of drugs in clinical trials - also called clinical studies or clinical research - usually occurs in three and sometimes four different phases or steps. Each phase normally involves a larger number of people.

**Phase I.** In Phase I trials, researchers study how quickly an investigational treatment works and how the human body processes the investigational treatment. They also try to find dose ranges that will produce the desired effects. Phase I trials typically involve healthy volunteers, but sometimes severely ill patients will participate in these trials.

503

**Phase II.** In these trials, the safety and effectiveness of an investigational treatment is studied in larger groups of people who have the disease or condition to be treated.

**Phase III.** In Phase III trials, the safety and effectiveness of an investigational treatment are studied in larger populations of people for whom the drug is intended. Typically, there are hundreds or thousands of people in a Phase III trial. Often, the investigational treatment is compared with standard treatments in hopes of finding better ways to help people. The pharmaceutical or biotechnology company that is sponsoring the trial reports the findings from Phase III trials to the U.S. Food and Drug Administration (FDA).

**Phase IV.** Phase IV trials are also called post-marketing trials. Only after the FDA has determined that the medicine is both safe to use and equivalent or superior to existing therapies is it then made available for broader use by physicians and their patients. Phase IV trials take place after a drug has been approved. Findings from Phase IV trials provide additional information about the safety and efficacy of the drug.

FIG. 5D

© Back to top

## How are participant's rights and safety protected during a clinical trial ?

503

The FDA is the government agency that develops policies and guidelines that protect the rights, safety, and well-being of people involved in clinical research. The rights and safety of people participating in clinical trials are also protected by an Institutional Review Board and by an informed consent form. An Institutional Review Board (IRB) is comprised of both physicians and lay people for the purpose of studying the design of the trial and ensuring that participant's rights are maintained. The informed consent form explains the clinical trial and outlines a participant's rights. You should always be given an informed consent form prior to enrolling in any clinical trial.

© Back to top

## Who pays for clinical trials ?

- Sponsors fund clinical trials. This funding can come from the federal government via the National Institutes of Health (NIH) or directly from pharmaceutical and biotech companies.
- The clinical trial sponsor contracts with specialized physicians and/or researchers to administer the trial. Settings for the trials could range from the physician's office to a hospital or research facility. Reimbursement for this service is typically paid out on a per-patient basis.

- Sponsors may pay you to participate in a clinical trial. Typically, these fees, when provided, are nominal.
- Medical care is often provided at no cost to the patients, but they still may be responsible for other expenses such as travel between their homes and the health care facility.

Patients may also have to pay for some medical procedures, tests, or hospital stays if these are considered a part of standard treatment and not part of the clinical trial. Before you enroll, you should determine exactly who pays for what services.

© Back to top

### Where can you get more information about clinical trials ?

If you or someone you know has a medical problem and is thinking about taking part in a clinical trial, speak to your health care provider first. In taking an active role in the management of your health, you may want to work closely with your provider to find out if a particular clinical trial is right for you.

© Back to top

## Questions you need to ask.

503

- What is the length of your involvement in the clinical trial ? How long will the trial last ?
- Where will you have to go in order to participate in the clinical trial ?
- What are the possible treatments you may receive while in the clinical trial ?
- Do the treatment alternatives they provide cover all possible treatments for this disease ? If not, what are your other treatment alternatives ?
- What procedures are built into the study to keep you safe from harm while you are participating ?
- What are the risks and benefits of participating in the clinical trial ?
- If there are risks, what will happen should you have an adverse reaction to the treatment in the study ?
- What costs may you incur if you participate ?
- Will the treatment be available to you even after the clinical trial has concluded ?
- Where are the funds coming from to conduct this trial ? What is their purpose in sponsoring the trial ?

You should also feel free to ask any other question about the trial you want answered.

© Back to top

### Common terms used in clinical trials.

503

**Clinical trial:** A clinical trial - also called a clinical study or clinical research - is a way to evaluate the safety and benefits of a new drug in a carefully controlled setting. The new drug is tested in people who volunteer to participate in the trial.

**Clinical investigator:** A clinical investigator is a doctor or scientist who is responsible for carrying out the planned research activities for a clinical trial. Typically, the doctors chosen for these clinical activities are experts within their medical specialties.

**Coordinator:** A coordinator is a person (usually a nurse or other medical professional) who is responsible for organizing the planned clinical research activities for a trial. The coordinator is also responsible for taking care of important study documents.

**Food and Drug Administration:** The Food and Drug Administration is often referred to as the FDA. The FDA is a government agency that develops policies and guidelines that protect the rights, safety, and well-being of people involved in clinical research. The FDA also enforces the laws that govern the approval, regulation and monitoring of drugs and medical devices.

**Informed Consent:** Informed consent is a process that confirms a patient understands the nature of a study, the risks involved, and the expected benefits of treatment. A written and dated form called the "informed consent form" is signed by a patient to document this process.

**Institutional Review Board:** An Institutional Review Board is usually referred to as the "IRB." The IRB is a group of medical, scientific, and nonscientific people that are responsible for reviewing and approving the planned clinical activities of a study. The group ensures the protection of the rights, safety, and well-being of patients who volunteer for clinical trials.

**Investigational treatment:** Investigational treatment is another term for the drug, treatment, or medical device that is studied in a clinical trial.

**Principal investigator:** The principal investigator is the doctor or researcher who is put in charge of all clinical activities at a particular study location and who supervises the care of patients in the study.

**Protocol:** A protocol is a plan that contains guidelines for a clinical study. The pharmaceutical or biotechnology company that discovered the investigational treatment usually develops the protocol.

503

**Sponsor:** The sponsor is the organization that funds a clinical trial and that develops a plan for the research. The organizations can be a pharmaceutical or biotech company, a research institution, or other health organization.

**Standard treatment:** Standard treatment is a term that refers to approved medical procedures, drugs, tests, or hospitalizations that are a part of the general care considered to be appropriate for certain diseases and conditions. It is the "best treatment" currently known for a given disease. If there are no current treatments shown to be effective against a particular disease, then no treatment would be the standard treatment for that condition.

© Back to top

FIG. 5J

CLINICAL

Search

Home / Cancer /

**Clinical Trials**

Feature Stories  600

News Archive

Ask the Expert

About Clinical Trials  601

Tutorial

Therapeutic Area

Cancer  602

Neurological Conditions  603

Contact me for a clinical trial  604

**Welcome to Clinical Trials**

When a promising new medication is identified, careful evaluation of the safety and effectiveness of the drug then occurs in the clinical trials process. Typically, the doctors chosen to conduct clinical trials are experts within their medical specialties. Findings from the clinical trials are reported by the pharmaceutical or biotechnology company that is sponsoring the clinical trial to the US Food and Drug Administration - the FDA. Only after the FDA has determined from reviewing the findings from clinical trials that the medicine is both safe to use and effective is it then

Register Now  
 Review Clinical Trials Ask Questions and More

FIG. 6A

made available for broader use by doctors and their patients.

Doctors conducting clinical trials frequently ask their patients if they are interested in volunteering to participate in a clinical trial. Each trial has different requirements for how it is conducted, such as conditions for patient eligibility, length of the study, dosage of the study drug, and types of medical procedures, to name a few. If you are interested in participating in a clinical trial, it is very important that you review these requirements with the doctor conducting the clinical trial to ensure your eligibility and to determine the potential benefits and risks from the trial.

If you are looking for information on where clinical trials are taking place and the types of trials that are available, you can search our clinical trials listing. If you want to learn more about clinical trials, please see our *About Clinical Trials* page. These are the first steps in learning about clinical trials and in deciding how medical research on possible treatments for tomorrow may help you today.

[About Clinical Trials](#) will provide you with more information.

FIG. 6B

Search	<input type="button" value="go"/>	<input type="button" value="Search clinical trials"/> <input type="button" value="go"/>
<p><b>General Trial Interest Form</b></p> <p>Please select the therapeutic areas and the specific conditions that interest you. Select up to three conditions below. Your selection(s) will be saved to the Medical Conditions section of My Profile, where you can select additional conditions.</p> <p>Primarily interested</p> <p><input checked="" type="radio"/> for myself  <input type="radio"/> for someone else</p>		
<p>605</p> <p>606</p> <p>607</p> <p>608</p> <p>609</p>		
<p>Select therapeutic area <input type="button" value="go"/></p> <p>Select therapeutic area <input type="button" value="go"/></p> <p>Select therapeutic area <input type="button" value="go"/></p> <p>How would you like us to contact you ?</p> <p><input checked="" type="checkbox"/> by email  <input type="checkbox"/> by phone  <input type="checkbox"/> by regular mail</p> <p>First Name _____  Last Name _____</p>		
<p>Therapeutic Area</p> <p><input type="radio"/> Cancer  <input type="radio"/> Neurological Conditions</p> <p><input type="checkbox"/> Register Now  <input type="checkbox"/> Review Clinical Trials Ask Questions and More</p>		

FIG. 6C

23/114

609

Phone #

ext.

Email

Address

City

State

ZIP CODE

Best time to    
contact you

Willing to    
travel

Submit  Cancel  611

610

FIG. 6D


<p>Search <input type="text"/>  go</p> <p><b>Register</b></p> <p><b>Welcome !</b></p> <p>To register with <u>                  </u> we invite you to complete the following questionnaire about you and <u>your health</u>. This should take approximately 5 minutes to complete. <u>                  </u> will use the information to present you with new medical therapy and <u>clinical trial</u> information that is of specific interest to you.</p> <p>Your privacy and security are very important to us; therefore we encourage you to review our <u>Privacy &amp; Security Policy</u>.</p> <p><b>Choose Your Username and Password</b></p> <p>Please choose a username <input type="text"/></p> <p>Please choose a password <input type="text"/></p> <p>Please re-type your password <input type="text"/></p> <p>Choose your reminder question <input type="text"/> What is your mother's maiden name ?  <input type="text"/></p> <p>Please enter your answer to the question <input type="text"/></p> <p><b>Are you seeking information for yourself, or for someone else ?</b></p> <p><input type="radio"/> I am seeking information for myself</p> <p><input type="radio"/> I am seeking information for someone else</p> <p><b>Continue</b></p>
<p><input type="radio"/> Feature Articles</p> <p><input type="radio"/> Medical News</p> <p><input type="radio"/> Ask the Expert</p> <p><input type="radio"/> All About Clinical Trials</p> <p><input type="radio"/> Tutorial</p> <p><b>Therapeutic Area</b></p> <p><input type="radio"/> Cancer</p> <p><input type="radio"/> Neurological Conditions</p> <p><b>Register Now</b></p> <p>Review Clinical Trials Ask Questions and More</p>

FIG. 6E

<input style="width: 100px; height: 30px; border: 1px solid black; border-radius: 5px; padding: 5px; margin-bottom: 5px;" type="button" value="Search"/> <div style="border: 1px solid black; padding: 5px; display: inline-block;"> <input style="border: none; background-color: transparent; color: inherit; font-size: inherit; font-weight: inherit; line-height: inherit; margin-right: 10px;" type="button" value="go"/> <input style="width: 150px; border: 1px solid black; border-radius: 5px; padding: 5px; margin-right: 10px;" type="text"/> <input style="border: 1px solid black; border-radius: 5px; padding: 5px;" type="button" value="Search clinical trials"/> </div>	<b>Step 2 of 3</b>	
<p><b>Personal Information/Medical Conditions</b></p> <p>* denotes required information</p>		
<p><b>Personal Information</b></p>		
<p><input type="radio"/> Feature Articles</p> <p><input type="radio"/> Medical News</p> <p><input type="radio"/> Ask the Expert</p> <p><input type="radio"/> All About Clinical Trials</p> <p><input type="radio"/> Tutorial</p> <p><b>Therapeutic Area</b></p> <p><input type="radio"/> Cancer</p> <p><input type="radio"/> Neurological Conditions</p>	<p>Salutation</p> <p>First Name *</p> <p><input type="button" value="Pick one-"/> <input style="width: 150px; border: 1px solid black; border-radius: 5px; padding: 5px; margin-right: 10px;" type="text"/></p> <p>(Please enter your first name or the name you prefer to be called when you are welcomed to the site.)</p> <p><input style="width: 150px; border: 1px solid black; border-radius: 5px; padding: 5px; margin-right: 10px;" type="text"/></p> <p>Last Name</p> <p>Birthdate (month/year)*</p> <p>Gender*</p> <p>Ethnic Background</p>	<p><input type="button" value="Pick one-"/> <input style="width: 150px; border: 1px solid black; border-radius: 5px; padding: 5px; margin-right: 10px;" type="text"/></p> <p><input type="button" value="Pick one-"/> <input style="width: 150px; border: 1px solid black; border-radius: 5px; padding: 5px; margin-right: 10px;" type="text"/></p> <p><input type="button" value="Pick one-"/> <input style="width: 150px; border: 1px solid black; border-radius: 5px; padding: 5px; margin-right: 10px;" type="text"/></p>
<p><b>Contact Information</b></p> <p>Email Address *</p> <p>Telephone Number</p> <p>Postal or Zip Code *</p> <p>Country</p>		
<p><input type="radio"/> Register Now</p> <p>Review Clinical Trials Ask Questions and More</p>		

FIG. 6F

I do not want to receive information by e-mail.

**Medical Conditions**

By completing this section, you will help us to provide you with information that meets your interests.

I am interested in the following conditions \* (you may choose more than one);

**Medical Conditions: \***

Acne  
AIDS/HIV  
Allergies  
Alopecia (Hair Loss)

Add >

< Remove

Continue

**My Conditions:**

Alopecia (Hair Loss)  
Cancer: Prostate  
Seizures (Epilepsy)

FIG. 6G

27/114

<p>Search <input type="text"/> <input type="button" value="go"/></p> <p><b>Information Request</b></p> <p>I would like to receive information about my conditions:</p> <p><b>Alopecia (Hair Loss):</b></p> <p><input type="checkbox"/> Send me Clinical Trial Opportunities  <input type="checkbox"/> Send me News and New Medical Therapies  <input type="checkbox"/> Do not send me information</p> <p><b>Cancer - Prostate:</b></p> <p><input type="checkbox"/> Send me Clinical Trial Opportunities  <input type="checkbox"/> Send me News and New Medical Therapies  <input type="checkbox"/> Do not send me information</p> <p><b>Seizures (Epilepsy):</b></p> <p><input type="checkbox"/> Send me Clinical Trial Opportunities  <input type="checkbox"/> Send me News and New Medical Therapies  <input type="checkbox"/> Do not send me information</p> <p><b>Terms and Conditions</b></p> <p>Please read the following Terms and Conditions Agreement.</p>	<p><b>Step 3 of 3</b></p> <p>650</p> <p><b>TERMS AND CONDITIONS</b></p>
<p>By selecting "I Accept", you are accepting the Terms and Conditions above and will become a registered user.</p> <p><input type="checkbox"/> I Accept <input type="checkbox"/> I Do Not Accept</p>	

FIG. 6H

<input type="button" value="Search"/> <input type="button" value="Go"/>	<input type="button" value="Search clinical trials"/> <input type="button" value="Go"/>	<input type="checkbox"/> Feature Articles <input type="checkbox"/> Medical News <input type="checkbox"/> Ask the Expert <input type="checkbox"/> All About Clinical Trials <input type="checkbox"/> Tutorial <input type="checkbox"/> Therapeutic Area <input type="checkbox"/> Cancer <input type="checkbox"/> Neurological Conditions	<input type="checkbox"/> Register Now <input type="checkbox"/> Review Clinical Trials Ask Questions and More
<p><b>Registration Complete</b></p> <p>Thank you for registering with us.</p> <p>Your request to receive information about the conditions you selected is being processed; you should receive updates periodically.</p> <p>As a result of your interest in clinical trial opportunities, we would like to ask you additional questions about your health and medical condition(s). These questions are similar to what a doctor, or other medical professional would ask you when you are being screened for participation in a specific clinical trial. This information is important in determining your possible preliminary eligibility for a specific clinical trial.</p> <p>Please take a few more minutes to answer the next set of questions, and keep in mind that these are optional. If you do not have time to complete the additional questions right now, you may update your profile the next time you login to <a href="http://acurian.com">acurian.com</a>. Would you like to continue?</p> <p><input type="checkbox"/> Yes, Continue   <input type="checkbox"/> No, Return to Previous Activity</p>			

FIG. 61

Search <input type="text"/>	<input type="button" value="go"/>	Search clinical trials <input type="button" value="go"/>	Medications (Optional)																																								
<p><b>Step 1 of 5</b></p> <p>Are you taking prescription (Rx) or over-the-counter (OTC) medications for these conditions ?</p> <table border="1"> <thead> <tr> <th>Your Medical Conditions</th> <th>Prescription</th> <th>Over-the-Counter</th> <th>No Medications</th> </tr> </thead> <tbody> <tr> <td><input type="radio"/> Alopecia (Hair Loss)</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td><input type="radio"/> Cancer: Prostate</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td><input type="radio"/> Seizures (Epilepsy)</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Do you take medications for any of the following conditions:</p> <table border="1"> <thead> <tr> <th>Medication</th> <th>Yes</th> <th>No</th> </tr> </thead> <tbody> <tr> <td>Allergies or Asthma</td> <td><input type="radio"/></td> <td><input type="radio"/></td> </tr> <tr> <td>Heartburn</td> <td><input type="radio"/></td> <td><input type="radio"/></td> </tr> <tr> <td>Diabetes</td> <td><input type="radio"/></td> <td><input type="radio"/></td> </tr> <tr> <td>High Blood Pressure</td> <td><input type="radio"/></td> <td><input type="radio"/></td> </tr> <tr> <td>Pain</td> <td><input type="radio"/></td> <td><input type="radio"/></td> </tr> <tr> <td>Thyroid Disorders</td> <td><input type="radio"/></td> <td><input type="radio"/></td> </tr> <tr> <td>Heart Conditions</td> <td><input type="radio"/></td> <td><input type="radio"/></td> </tr> </tbody> </table> <p><input type="button" value="Save and Continue"/></p> <p><input type="button" value="Save and Return to Previous Activity"/></p>				Your Medical Conditions	Prescription	Over-the-Counter	No Medications	<input type="radio"/> Alopecia (Hair Loss)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="radio"/> Cancer: Prostate	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="radio"/> Seizures (Epilepsy)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Medication	Yes	No	Allergies or Asthma	<input type="radio"/>	<input type="radio"/>	Heartburn	<input type="radio"/>	<input type="radio"/>	Diabetes	<input type="radio"/>	<input type="radio"/>	High Blood Pressure	<input type="radio"/>	<input type="radio"/>	Pain	<input type="radio"/>	<input type="radio"/>	Thyroid Disorders	<input type="radio"/>	<input type="radio"/>	Heart Conditions	<input type="radio"/>	<input type="radio"/>
Your Medical Conditions	Prescription	Over-the-Counter	No Medications																																								
<input type="radio"/> Alopecia (Hair Loss)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
<input type="radio"/> Cancer: Prostate	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
<input type="radio"/> Seizures (Epilepsy)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
Medication	Yes	No																																									
Allergies or Asthma	<input type="radio"/>	<input type="radio"/>																																									
Heartburn	<input type="radio"/>	<input type="radio"/>																																									
Diabetes	<input type="radio"/>	<input type="radio"/>																																									
High Blood Pressure	<input type="radio"/>	<input type="radio"/>																																									
Pain	<input type="radio"/>	<input type="radio"/>																																									
Thyroid Disorders	<input type="radio"/>	<input type="radio"/>																																									
Heart Conditions	<input type="radio"/>	<input type="radio"/>																																									

FIG. 6J

Search	Search clinical trials	Go
<h3>Health Habits (Optional)</h3> <p>It is often important to know your health habits when presenting you with possible clinical trial opportunities.</p> <p>How often do you exercise ?</p> <p><input type="radio"/> Never  <input type="radio"/> Once a week  <input type="radio"/> Twice a week  <input type="radio"/> Three times a week  <input type="radio"/> Four or more times a week  <input type="radio"/> Daily</p> <p>How often do you visit your primary care physician ?</p> <p><input type="radio"/> Once a year  <input type="radio"/> 2-4 times a year  <input type="radio"/> Every month  <input type="radio"/> I do not have a primary care physician</p> <p>Do you smoke cigarettes ?</p> <p><input type="radio"/> No, I have never smoked  <input type="radio"/> No, I quit smoking  <input type="radio"/> Yes, daily  <input type="radio"/> Yes, occasionally</p> <p><input type="radio"/> Register Now  <input type="radio"/> Review Clinical Trials Ask Questions and More</p>		

FIG. 6K

If you smoke, how many cigarettes do you smoke per day ?

Please enter:  Cigarettes Per Day

If you smoke, how old were you when you started smoking ?

Please enter:  years old

Do you drink alcoholic beverages ?

- No
- Yes, occasionally
- Yes, 1-2 drinks per day
- Yes, more than 2 drinks per day

Overall, how would you rate your health ?

- Excellent
- Good
- Fair
- Poor

FIG. 6L

32/114

Search	go
Search clinical trials	
Clinical Trial Experience (Optional)	
<p>A clinical trial is a carefully structured study that evaluates the effectiveness of a drug against a specific disease or condition. Clinical trials can focus on a new drug or they may be used to determine new uses for existing medications.</p> <p>The following questions ask about your experience and interest in participating in clinical trials. These questions are to help us know how many members of ours have participated in clinical trials before.</p> <p>How many clinical trials have you participated in ?</p> <p><input type="radio"/> 0 <input type="radio"/> 1 <input type="radio"/> 2 - 3 <input type="radio"/> 4 or more</p> <p>How interested would you be in participating in a clinical trial for a drug that might be used to treat any medical condition(s) you may have ?</p> <p><input type="radio"/> Very interested <input type="radio"/> Somewhat interested <input type="radio"/> Not Sure <input type="radio"/> Not interested</p> <p><input type="radio"/> Register Now <input type="radio"/> Review Clinical Trials Ask Questions and More</p>	

FIG. 6M

If interested in clinical trial participation how far would you be willing to travel to participate in a clinical trial?

- 1 - 10 miles
- 11 - 50 miles
- 51 - 100 miles
- More than 100 miles
- Any distance

[Save and Continue](#)

[Save and Return to Previous Activity](#)

FIG. 6N

<input type="button" value="Search"/> <input type="text" value="Search clinical trials"/> <input type="button" value="go"/>	<h3>Step 4 of 5</h3> <h4>Clinical Trial Questions</h4> <p>Earlier in the registration process, you expressed interest in clinical trial opportunities. When you are screened for a clinical trial, the doctor at the trial site needs to know more information about your health and the medical condition(s) for which you have been diagnosed. Your answers to the following questions may help determine if you may potentially qualify for a specific clinical trial.</p> <p>Listed below are the conditions you selected earlier in the questionnaire. After you answer questions about each condition, a check mark will appear to the right. Your information will be saved after you complete each section. If you are unable to complete these at this time, we will ask you to update your profile the next time you login to <a href="http://acurian.com">acurian.com</a>.</p> <table border="1"> <tr> <td><input type="radio"/> Feature Articles</td> <td><input type="radio"/> Medical News</td> <td><input type="radio"/> Ask the Expert</td> <td><input type="radio"/> All About Clinical Trials</td> </tr> <tr> <td><input type="radio"/> Tutorial</td> <td><input type="radio"/> Therapeutic Area</td> <td><input type="radio"/> Cancer</td> <td><input type="radio"/> Neurological Conditions</td> </tr> </table> <p><input type="radio"/> Register Now</p> <p><input type="radio"/> Review Clinical Trials Ask Questions and More</p>	<input type="radio"/> Feature Articles	<input type="radio"/> Medical News	<input type="radio"/> Ask the Expert	<input type="radio"/> All About Clinical Trials	<input type="radio"/> Tutorial	<input type="radio"/> Therapeutic Area	<input type="radio"/> Cancer	<input type="radio"/> Neurological Conditions	<p><b>Questionnaire Complete</b></p> <p><input checked="" type="checkbox"/> Alopecia (Hair Loss)</p> <p><input type="checkbox"/> Cancer: Prostate</p> <p><input type="checkbox"/> Seizures (Epilepsy)</p> <p><input type="button" value="Save and Continue"/></p> <p><input type="button" value="Save and Return to Previous Activity"/></p>
<input type="radio"/> Feature Articles	<input type="radio"/> Medical News	<input type="radio"/> Ask the Expert	<input type="radio"/> All About Clinical Trials							
<input type="radio"/> Tutorial	<input type="radio"/> Therapeutic Area	<input type="radio"/> Cancer	<input type="radio"/> Neurological Conditions							

FIG. 60

Step 5 of 5

Search  go

Feedback

Search clinical trials

Feedback

Thank you for taking the time to complete your profile.

The information you entered will be saved in the My Profile of our site. You may update this information at any time by selecting the My Profile button at the top of the page. We ask that you review your profile at least once a month, so that we may have the most accurate information when trying to present you with clinical trial or medical information.

Acurian welcomes your feedback. Please provide us with any comments you would like to share about the questions asked in this registration process.

Feature Articles

Medical News

Ask the Expert

All About Clinical Trials

Tutorial

Therapeutic Area

Cancer

Neurological Conditions

Register Now

Review Clinical Trials

Ask Questions and More

Send to Acurian

Return to Previous Activity

Search   go

Search clinical trials  go

**Thank You**

Your message was sent successfully. Thank you for contacting us. Your comments will help us serve you better.

[Return to Previous Activity](#)

Feature Articles

Medical News

Ask the Expert

All About Clinical Trials

Tutorial

Therapeutic Area

Cancer

Neurological Conditions

Register Now

Review Clinical Trials Ask Questions and More

FIG. 6Q

612

Search   Search clinical trials  Home / Knowledge Center /

## Welcome to My Library

Here's your chance to create a library of your very own. My Library is where you can store all kinds of information found throughout the site. Whether it's clinical trial information, abstracts on news articles, drug information, perspectives from our medical experts or personal stories, links to the items you select will be saved in this area for as long as you choose to keep them there. All you have to do is click the "Save to My Library" button found throughout the site.

In addition, you can type in personal notes along with the items you save. We will not access, use, or review your personal notes for any reason.

If you'd like to go directly to one of the five sections, select a link below:

- Feature Stories
- News Archive
- Ask the Expert
- About Clinical Trials
- Tutorial
- Therapeutic Area
- Cancer
- Neurological Conditions

Register Now  
 Review Clinical Trials Ask Questions and More

- News
- Drug Information
- Clinical Trials
- Ask The Expert
- Feature Stories
- Do not show this page again.

FIG. 6R

./././ Investigator Questionnaire  
**Investigator Questionnaire**

Step 1 of 3

Thank you for your interest in joining our investigator data base. The following questionnaire will take approximately one hour to complete. The privacy and security of your information is important to us. All information you submit is transmitted over a secure server. For more information, read our

Asterisks (\*) denote required fields.

Last Name \*

First Name \*

Middle Name

Degree(s) \*

701

702

703


Primary Research  
Facility's Organization or  
Institutional Name \*

Street Address \*

City \*

State/Province/Region\*

Country\*

703

-Select State/Province-	▼
-Select Country-	▼

Register
Services
FAQ

FIG. 7A

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358

1359

1360

1361

1362

1363

1364

1365

1366

1367

1368

1369

1370

1371

1372

1373

1374

1375

1376

1377

1378

1379

1380

1381

1382

1383

1384

1385

1386

1387

1388

1389

1390

1391

1392

1393

1394

1395

1396

1397

1398

1399

1400

1401

1402

1403

1404

1405

1406

1407

1408

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

1437

1438

1439

1440

1441

1442

1443

1444

1445

1446

1447

1448

1449

1450

1451

1452

1453

1454

1455

1456

1457

1458

1459

1460

1461

1462

1463

1464

1465

1466

1467

1468

1469

1470

1471

1472

1473

1474

1475

1476

1477

1478

1479

1480

1481

1482

1483

1484

1485

1486

1487

1488

1489

1490

1491

1492

1493

1494

1495

1496

1497

1498

1499

1500

1501

1502

1503

1504

1505

1506

1507

1508

1509

1510

1511

1512

1513

1514

1515

1516

1517

1518

1519

1520

1521

1522

1523

1524

1525

1526

1527

1528

1529

1530

1531

1532

1533

1534

1535

1536

1537

1538

1539

1540

1541

1542

1543

1544

1545

1546

1547

1548

1549

1550

1551

1552

1553

1554

1555

1556

1557

1558

1559

1560

1561

1562

1563

1564

1565

1566

1567

1568

1569

1570

1571

1572

1573

1574

1575

1576

1577

1578

1579

1580

1581

1582

1583

1584

1585

1586

1587

1588

1589

1590

1591

1592

1593

1594

1595

1596

1597

1598

1599

1600

1601

1602

1603

1604

1605

1606

1607

1608

1609

1610

1611

1612

1613

1614

1615

1616

1617

1618

1619

1620

1621

1622

1623

1624

1625

1626

1627

1628

1629

1630

1631

1632

1633

1634

1635

1636

1637

1638

1639

1640

1641

1642

1643

1644

1645

1646

1647

1648

1649

1650

1651

1652

1653

1654

1655

1656

1657

1658

1659

1660

1661

1662

1663

1664

1665

1666

1667

1668

1669

1670

1671

1672

1673

1674

1675

1676

1677

1678

1679

1680

1681

1682

1683

1684

1685

1686

1687

1688

1689

1690

1691

1692

1693

1694

1695

1696

1697

1698

1699

1700

1701

1702

1703

1704

1705

1706

1707

1708

1709

1710

1711

1712

1713

1714

1715

1716

1717

1718

1719

1720

1721

1722

1723

1724

1725

1726

1727

1728

1729

1730

1731

1732

1733

1734

1735

1736

1737

1738

1739

1740

1741

1742

1743

1744

1745

1746

1747

1748

1749

1750

1751

1752

1753

1754

1755

1756

1757

1758

1759

1760

1761

1762

1763

1764

1765

1766

1767

1768

1769

1770

1771

1772

1773

1774

1775

1776

1777

1778

1779

1780

1781

1782

1783

1784

1785

1786

1787

1788

1789

1790

1791

1792

1793

1794

1795

1796

1797

1798

1799

1800

1801

1802

1803

1804

1805

1806

1807

1808

1809

1810

1811

1812

1813

1814

1815

1816

1817

1818

1819

1820

1821

1822

1823

1824

1825

1826

1827

1828

1829

1830

1831

1832

1833

1834

1835

1836

1837

1838

1839

1840

1841

1842

1843

1844

1845

1846

1847

1848

1849

1850

1851

1852

1853

1854

1855

1856

1857

1858

1859

1860

1861

1862

1863

1864

1865

1866

1867

1868

1869

1870

1871

1872

1873

1874

1875

1876

1877

1878

1879

1880

1881

1882

1883

1884

1885

1886

1887

1888

1889

1890

1891

1892

1893

1894

1895

1896

1897

1898

1899

1900

1901

1902

1903

1904

1905

1906

1907

1908

1909

1910

1911

1912

1913

1914

1915

1916

1917

1918

1919

1920

1921

1922

1923

1924

1925

1926

1927

1928

1929

1930

1931

1932

1933

1934

1935

1936

1937

1938

1939

1940

1941

1942

1943

1944

1945

1946

1947

1948

1949

1950

1951

1952

1953

1954

1955

1956

1957

1958

1959

1960

1961

1962

1963

1964

1965

1966

1967

1968

1969

1970

1971

1972

1973

1974

1975

1976

1977

1978

1979

1980

1981

1982

1983

1984

1985

1986

1987

1988

1989

1

How many Investigators  Investigators → 707

Is the Investigator affiliated with:  
(check all that apply)

Local IRB    Central IRB  
 IEC (Canadian sites only)

If affiliated with a local IRB, what is its name ?

How often does the local IRB meet ?

Weekly    Bi-weekly  
 Monthly    As needed  
 Other

If "other", frequency of local IRB meeting ?

How soon after the IRB meeting will you receive an approval letter ?

708

Has the Investigator ever been audited by the Food & Drug Administration (FDA) or any other regulatory agency ?

Yes    No

709

1. If yes, what was the date of the audit ?	[ ]	709
Who was the auditor ?	[ ]	
If audited, was a 483 issued ?	<input type="radio"/> Yes <input type="radio"/> No	
What were the results of the audit ?	[ ]	
2. If yes, what was the date of the audit ?	[ ]	710
Who was the auditor ?	[ ]	
If audited, was a 483 issued ?	<input type="radio"/> Yes <input type="radio"/> No	
What were the results of the audit ?	[ ]	
Has the Investigator gone through an audit by a sponsor or CRO ?	<input type="radio"/> Yes <input type="radio"/> No	
1. If yes, what was the date of the audit ?	[ ]	
Who was the auditor ?	[ ]	

What were the results of the audit ?

2. If yes, what is the date of the audit ?

Who was the auditor ?

What were the results of the audit ?

Is your PRF

If PRF is multi-specialty, indicate specialties. (one per line)

Is your facility part of

Is the facility affiliated with a Site Management Organization (SMO) or research group ?

If affiliated, please specify the SMO name

If affiliated, is this an exclusive relationship ?

710

711

Single specialty

Multi-specialty

Solo practice

Group practice

Yes  No

Yes  No

Save and Continue

Cancel

```
graph TD; Q1[What were the results of the audit ?] --- Q2[2. If yes, what is the date of the audit ?]; Q2 --- Q3[Who was the auditor ?]; Q3 --- Q4[What were the results of the audit ?]; Q4 --- Q5[Is your PRF]; Q5 --- Q6[If PRF is multi-specialty, indicate specialties. (one per line)]; Q6 --- Q7[Is your facility part of]; Q7 --- Q8[Is the facility affiliated with a Site Management Organization (SMO) or research group ?]; Q8 --- Q9[If affiliated, please specify the SMO name]; Q9 --- Q10[If affiliated, is this an exclusive relationship ?]; Q10 --- B1[710]; Q10 --- B2[711]; B1 --- Q1; B1 --- Q2; B1 --- Q3; B1 --- Q4; B1 --- Q5; B2 --- Q6; B2 --- Q7; B2 --- Q8; B2 --- Q9; B2 --- Q10; B3 --- B4[Save and Continue]; B3 --- B5[Cancel];
```




FIG. 7F




FIG. 7G




FIG. 7H




FIG. 7I




FIG. 7J

48/114




FIG. 8A

49/114

FROM 816  
FIG. 8A




FIG. 8B

<p>Welcome</p> <p><a href="#">Home</a> / <a href="#">Active Trials</a> / <a href="#">Create Trial Parameters</a></p> <p><b>Create Trial Parameters</b></p> <p>To create an Active Trials files for a specific protocol please enter or select (from a drop down box) information to create trial parameters.</p> <p><i>All fields required</i></p>	
<p>Protocol Number</p> <p><input type="text"/></p> <p>Protocol Title</p> <p><input type="text"/></p> <p>Therapeutic Area</p> <p><input type="text"/></p> <p>Disease</p> <p><input type="checkbox"/> Indication</p> <p>Projected</p> <p>Number of Sites</p> <p><input type="text"/></p> <p>Projected</p> <p>Number of Patients per Site</p> <p><input type="text"/></p>	<p><input type="button" value=""/></p>
<p><input type="button" value="Register"/></p> <p><input type="button" value="Services"/></p> <p><input type="button" value="FAQ"/></p>	

FIG. 9A

Projected Trial Start Date	<input type="text" value="January"/> <input type="button" value="▼"/> <input type="text" value="2000"/> <input type="button" value="▼"/> <input )"="" type="text" value="Month/Year"/>
Projected Trial Stop Date	<input type="text" value="January"/> <input type="button" value="▼"/> <input type="text" value="2000"/> <input type="button" value="▼"/> <input )"="" type="text" value="Month/Year"/>
Projected Enrollment Period (in months)	<input type="text"/>
Trial Phase	<input type="text"/> - Select Trial Phase - <input type="button" value="▼"/>

Save Trial

Save and Search for Investigators

FIG. 9B

**Step 1:**  
To identify potential investigators - please select a specialty.

Addiction Psychiatry	<input type="checkbox"/>
Adolescent Medicine	<input type="checkbox"/>
Aerospace Medicine	<input type="checkbox"/>
Allergy & Immunology	<input type="checkbox"/>

Note: To select more than one specialty, point to the specialty and press control click. Limit of 2 selections.

**Step 2:**  
To include the prescribing behavior data in the investigator search results class relevant to the therapeutic area and indication. (optional)

- No Drug Class -	<input type="checkbox"/>
Acne Therapy	<input type="checkbox"/>
Aids Therapies	<input type="checkbox"/>
All Other Misc. Ethical Drugs	<input type="checkbox"/>

Note: To select more than one specialty, point to the specialty and press control click. Limit of 2 selections.

**Step 3:**  
To include the number of trials conducted by the investigator in the search, enter a number. (optional)

1	<input type="checkbox"/>
---	--------------------------

FIG. 10A

**Step 4:**

To access additional databases to enhance the investigator selection process, enter selections below. (optional)

**Patient Therapeutic Area**

**Patient Disease Indication**

**Patient Disease Indication Encounter Category**

Note: To select more than one patient disease encounter category, point to the specialty and press control click. Limit of 2 selections.

53/114

- Select a Category - Case Load Estimates - Malignancy of hepatobiliary system of pancreas Inpatient Discharge Diagnosis - Malignant neoplasm of pancreas

**Patient Distance from Site (in miles)**

**Step 5:**  
To limit search by geographical location - please enter your selections below.

**Municipal Area**

FIG. 10B

Welcome

Protocol Number  
**1234-5678**

- Register
- Services
- FAQ
- Security & Privacy Policy
- Active Trials
- Create Trial

Home /

/ Active Trials / Trial at a Glance / Search

## Investigator Search Results

The following investigator search results reflect the investigator search criteria and the patient demographic data selected in the Investigator Search. Review selections by scrolling down this page or by clicking here: [Investigator Search Criteria Summary](#). Click a column heading to sort by that column.

Displaying 1-20 out of 682 results

Search Results		Name	Specialty	City, State	Trials	Trials
First Name	Last Name					Count
Jones	J	Jones, J	Cardiovascular Disease	SEATTLE, WA	33	
Haspel	J	Haspel, J	Cardiovascular Disease	LA JOLLA, CA	28	
Turco	C	Turco, C	Cardiovascular Disease	SALT LAKE CI, UT	27	
Schelker	J	Schelker, J	Cardiovascular Disease	MILWAUKEE, WI	27	
Tucker	J	Tucker, J	Cardiovascular Disease	CINCINNATI, OH	25	
Robinson	C	Robinson, C	Cardiovascular Disease	MCMURRAY, PA	25	
Michelson	L	Michelson, L	Cardiovascular Disease	OKLAHOMA CIT, OK	24	
Kleger	B	Kleger, B	Cardiovascular Disease	PITTSBURGH, PA	22	
Doe	J	Doe, J	Cardiovascular Disease	SARASOTA, FL	20	
Smith	S	Smith, S	Cardiovascular Disease	HILLSBORO, OR	19	
Greene	M	Greene, M	Cardiovascular Disease	FOX POINT, WI	19	
Watson	T	Watson, T	Cardiovascular Disease	FORT WAYNE, IN	17	
Nicholas	J	Nicholas, J	Cardiovascular Disease	BALTIMORE, MD	16	
Hamilton	P	Hamilton, P	Cardiovascular Disease	DURHAM, NC	16	
Tang	H	Tang, H	Cardiovascular Disease	REDONDO BEAC, CA	15	
Wilcox	J	Wilcox, J	Cardiovascular Disease	PEORIA, IL	13	
Singer	J	Singer, J	Cardiovascular Disease	SANTA ROSA, CA	13	
Restrepo	A	Restrepo, A	Cardiovascular Disease	CHARLESTON, SC	13	
Grossman	D	Grossman, D	Cardiovascular Disease	BUFFALO, NY	12	
				SELLERSVILLE, PA	12	

Next 20 >

FIG.

TO  
FIG. 11B

54/114




FIG. 11B

Welcome / [Home](#) / [Active Trials](#) / [Trial at a Glance](#) / [Document Tracking](#)

## A multi-center study ... Document Summary

Summary of document status for the selected protocol. Click on any document to go to Document View by Investigator. Click on any investigator to go to specific Investigator Document View. Study launch documents have been grouped into categories denoted by the tabs below. Click on a tab to view status of documents in that category.

Feasibility	Regulatory	Financial	Vendor Info	CV/Signature	IRB	Misc																																	
						Other 1																																	
						Other 6																																	
						Other 5																																	
						Other 4																																	
						Other 3																																	
						Other 2																																	
						Other 1																																	
						Trial Synopsis																																	
						Conf. Agreement																																	
						Questionnaire																																	
<p><b>Legend</b></p> <table border="1"> <tr> <td>S = Sent</td> </tr> <tr> <td>R = Received</td> </tr> <tr> <td>C = Completed</td> </tr> </table> <p>Investigator</p> <table> <tr> <td>Smith, J.</td> <td>S</td> </tr> <tr> <td>Robinson, M.</td> <td>S</td> </tr> </table> <p>Investigators:</p> <table> <tr> <td>A</td> <td>B</td> <td>C</td> <td>D</td> <td>E</td> <td>F</td> <td>G</td> <td>H</td> <td>I</td> <td>J</td> <td>K</td> <td>L</td> <td>M</td> <td>N</td> <td>O</td> <td>P</td> <td>Q</td> <td>R</td> <td>S</td> <td>T</td> <td>U</td> <td>V</td> <td>W</td> <td>X</td> <td>Y</td> <td>Z</td> </tr> </table>							S = Sent	R = Received	C = Completed	Smith, J.	S	Robinson, M.	S	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
S = Sent																																							
R = Received																																							
C = Completed																																							
Smith, J.	S																																						
Robinson, M.	S																																						
A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z														

[Return to Trial at a Glance](#)

FIG. 12

Welcome

[Home / Active Trials / Trial at a Glance / Document Tracking / Document View by Investigator](#)

Protocol Number

345678

### Document View by Investigator

Summary of document status by investigator. Click on any investigator to go to document history of the document selected in the drop down box. Study launch documents have been grouped into categories denoted by the tabs below. Click on a tab to view status of documents in that category.

- Register
- Services
- FAQ
- Document Summary
- Document View
- Investigator View

Document:	Questionnaire	▼	<input checked="" type="radio"/> Create New Document
Investigator	<u>Date Sent</u>	<u>Date Rec'd</u>	<u>Date Completed</u>
Smith, J.	1/27/01	1/27/01	1/28/01
Investigators:			
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z			

FIG. 13

From: Service Provider      Sent: June 6, 2000  
To: Ms. Moore  
Subject: Clinical Trial Opportunity

Dear Ms. Moore:

You may qualify for an upcoming clinical trial opportunity. For additional information go to [http://www.website.com/study/zz-234567-22\\*](http://www.website.com/study/zz-234567-22*) and complete the study specific questionnaire.

Contact service.com with any questions or comments you may have.

Sincerely,

Service Provider

If you have received this message in error or no longer would like to be considered or contacted about clinical trials please go to <http://www.service.com/remove>

FIG. 14

### Questionnaire - Alzheimer's

In order to evaluate whether you may be eligible for this study, we will need to review some of your medical history. Are you legally able to provide us with this information for the potential study participant?

Yes, I am the potential study participant.

Yes, I am a caregiver for the potential study participant with the ability to provide the potential participant's information for the purpose of seeking enrollment in clinical studies.

No, I am not legally able to provide this information.

In answering the following questions, "you" or "your" refers at all times to the potential study participant.

Please provide your gender.

- Male
- Female

How did you hear about this study?

- Internet
- Newspaper Ad
- Newspaper Article
- Radio Ad
- Radio Public Service Announcement
- TV Ad
- TV program
- Physician
- Friend
- Support Group
- Patient Ed Materials
- Cardiology Newsletter
- Other, please specify: \_\_\_\_\_

The purpose of this medical research study is to evaluate the effect of an investigational drug on the ability to reason, remember, imagine, and learn in humans who have already been diagnosed with mild to moderate probable Alzheimer's Disease. You must live with a caregiver or receive daily visits from a responsible caregiver. The caregiver must be familiar with your recent medical history and be willing to come to 7 doctor visits for a period of 6 months.

After these questions are answered we may be able to refer you to a research site for further screening. After the site reviews your responses to the screening questions, a nurse or other person at the research facility will be calling you. At that time, it will be determined if a first visit should be scheduled to determine whether this study is appropriate for you.

Have you been diagnosed with Alzheimer's disease ?

- Yes
- No

Have you experienced a deterioration in memory over at least the last 6 months ?

- Yes
- No

Click the box next to the following if you have experienced a decline in any of the following in at least the last 6 months:

- orientation
- judgement
- problem solving
- functioning in community affairs
- functioning in home or hobbies
- functioning in personal care

FIG. 15B

Do you live in a residential home ?

Yes  
 No

Click the box next to the person who will serve in the role of Caregiver:

I am the Caregiver  
 Friend  
 Relative  
 Paid personnel  
 No Caregiver

1. Please enter your date of birth:

Day                    Month                    Year (pull-down boxes)

If female, continue with question 2  
 If male, continue with question 6

2. Are you/Is (Patient) surgically sterile or post-menopausal for 1 year or more ?

Yes - continue with question #6  
 No - continue with question #3

3. Do you/Does (Patient) have any other neurological conditions such as:

Parkinson's disease  
 Pick's disease  
 Huntingtons chorea  
 Down's syndrome  
 Creutzfeldt-Jacob disease  
 Other \_\_\_\_\_

FIG. 15C

4. Do you now or did you at any time, have one or more of the following conditions resulting in your memory or *cognitive* impairment:

- Major head injury
- Injury caused by trauma such as boxing
- Vitamin deficiency
- Type (drop down menu)
- Brain abscess
- Syphilis
- Meningitis
- AIDS
- Brain cancer
- Thyroid, parathyroid, or pituitary disease
- Cushing's syndrome
- Kidney failure
- Uncontrolled diabetes
- Mental retardation

5. Do you have a history of any of the following:

- Stroke within the past 12 months
- Epilepsy or convulsions (Childhood convulsions caused by fever continue)
- Major depression
- Stomach ulcer that is currently being treated
- Liver, kidney, or lung disease
- Kidney stones

6. Have you had a heart attack or coronary artery bypass graft surgery within the past 6 months ?

- No
- Yes

7. Do you experience angina (chest pain) that required a change in medication in the past 3 months ?

Yes  
 No

8. Has a doctor told you that you have a heart rate that is slow or less than 50 beats per minute ?

Yes  
 No

9. Do you take medication for high blood pressure or chronic low blood pressure ?

Yes  
 Medication(s) taken: (drop down menu)  
 No  
 Don't know

10. Do you take any medications for the purpose of treating memory loss such as dementia ?

Yes  
 No

11. Are you allergic to any medications ?

Yes  
 Medication(s) (drop down menu)  
 No

FIG. 15E

12. Are you taking any other medications including vitamins or herbal supplements such as Ginkgo Biloba ?

- Yes
- Which Medication(s) (drop down menu)
- No

13. Have you ever been enrolled in a research study for galantamine ?

- Yes
- No
- Don't know

14. Have you taken an investigational drug in the past 30 days or are you taking one now ?

- No, I have not taken an investigational drug in the past 30 days
- Yes, I have taken an investigational drug in the past 30 days
- Yes, I am taking an investigational drug now

15. How many drinks do you consume in a typical 24-hour period ?

- 1-2 drinks
- 3-5 drinks
- 6-8 drinks
- more than 8 drinks

16. Have you/patient had a CT scan or MRI of the head during the last 12 months ?

- Yes
- No

FIG. 15F

Questionnaire - Alzheimer's

SCREEN #2: PATIENT NOT ELIGIBLE FOR STUDY

We appreciate your interest in this study. Unfortunately, from the information you have provided, you are not a candidate for participation in this study. May we have your permission to contact you in the future with information about this or other studies?

- Yes, contact me.
- No, I do not want to be contacted.

FIG. 15G

Questionnaire - Alzheimer's

SCREEN #3: PATIENT POTENTIALLY ELIGIBLE FOR STUDY:

Based on your responses, you may be eligible for the clinical study. We will forward this information to the research site you selected. The research site will contact you shortly to ask you further questions about your health, and possibly to schedule an appointment for the first visit. In the meantime, we will send you a Welcome Kit that contains information about the study. If the site does not contact you within 5-7 business days, please feel free to call the number that will be included in your mailed materials.

In the event that you do not participate in this particular study, may we have your permission to contact you in the future about other studies?

- Yes, contact me
- No, I do not want to be contacted

FIG. 15H




FIG. 16




FIG. 17




FIG. 18




FIG. 19

71/114




FIG. 20




FIG. 21A




FIG. 21B




FIG. 21C




FIG. 21D




FIG. 21E




FIG. 21F




FIG. 21G




FIG. 21H




FIG. 21




FIG. 21J




FIG. 21K




FIG. 21L




FIG. 21M




FIG. 21N




FIG. 210




FIG. 21P




FIG. 21Q

## INV\_STUDY\_PERFORMANCE

89/114

INVESTIGATOR\_ID: CHAR(18)  
 STUDY\_PRF\_ID: CHAR(18)

SOURCE\_CD: CHAR(18)  
 SPONSOR\_ID: CHAR(18)  
 SPONSOR\_CRO\_NAME: CHAR(18)  
 PROTOCOL\_NUMBER: CHAR(18)  
 STUDY\_PHASE\_CD: CHAR(18)  
 DRUG\_NAME: CHAR(18)  
 DRUG\_CLASS: CHAR(18)  
 THERA\_CONDITION\_CD: CHAR(18)  
 START\_DATE: CHAR(18)  
 NUM\_ENROLLMENT\_COMMITMENT: CHAR(18)  
 NUM\_PATIENTS\_ENROLLED: CHAR(18)  
 ENROLLMENT\_MONTHS: CHAR(18)  
 ENROLLMENT\_MET\_IND: CHAR(18)  
 TIMEFRAME\_MET\_IND: CHAR(18)  
 PLACEBO\_RESPONSE\_RATE: CHAR(18)  
 NUM\_PATIENTS\_EVALUABLE: CHAR(18)  
 MICROBIOLOGIC\_EVALUABLE: CHAR(18)  
 BACTERIAL\_EVALUABLE: CHAR(18)  
 NOTES: CHAR(18)  
 CREATE\_DATE: CHAR(18)  
 UPDATE\_DATE: CHAR(18)  
 CREATE\_BY: CHAR(18)  
 UPDATE\_BY: CHAR(18)

2220

## INV\_SPECIALTY

INVESTIGATOR\_ID: NUMBER(8)  
 SPECIALTY\_CD: VARCHAR2(6)

SOURCE\_CD: VARCHAR2(12)  
 BOARD\_COMPLETE\_CD: VARCHAR2(12)  
 CREATE\_DATE: DATE  
 UPDATE\_DATE: DATE  
 CREATE\_BY: INTEGER  
 UPDATE\_BY: INTEGER

TO 2210  
FIG. 22B

2230

## INV\_PATIENT\_POPULATION

INVESTIGATOR\_ID: CHAR(18)  
 INDICATION\_CD: CHAR2(18)

ANNUAL\_PATIENTS\_TREATED: CHAR(18)  
 ANNUAL\_NEW\_PATIENTS\_TREATED: CHAR(18)  
 INTERESTED\_IND: CHAR(18)  
 CREATE\_BY: CHAR(18)  
 UPDATE\_BY: CHAR(18)  
 CREATE\_DATE: CHAR(18)  
 UPDATE\_DATE: CHAR(18)

2240

FIG. 22A

90/114  
INV\_INVESTIGATOR

FROM  
2220, 2230, 2240  
FIG. 22A

INVESTIGATOR\_ID: CHAR(18)

2210

SOURCE\_CD: CHAR(18)  
HMS\_ID: CHAR(18)  
FIRST\_NAME: CHAR(18)  
MIDDLE1: CHAR(18)  
MIDDLE2: CHAR(18)  
LAST\_NAME: CHAR(18)  
SUFFIX: CHAR(18)  
COUNTRY: CHAR(18)  
SOC\_SEC\_NBR: CHAR(18)  
IND\_UPIN: CHAR(18)  
SEX: CHAR(18)  
DOB: CHAR(18)  
MED SCHOOL\_CD: CHAR(18)  
GRADUATION\_YEAR: CHAR(18)  
RSDNCY\_ORG: CHAR(18)  
RSDNCY\_CITY: CHAR(18)  
FLLWSHP\_ORG: CHAR(18)  
FLLWSHP\_CITY: CHAR(18)  
DEGREE1: CHAR(18)  
DEGREE2: CHAR(18)  
PHONE\_NBR: CHAR(18)  
PHONE\_EXTENSION: CHAR(18)  
FAX\_NBR: CHAR(18)  
EMAIL: CHAR(18)  
CREDENTIAL: CHAR(18)  
DELETE\_REASON\_CD: CHAR(18)  
DELETE\_REQUEST\_DATE: CHAR(18)  
WRONG\_NUMBER\_IND: CHAR(18)  
CV RECEIVED\_DATE: CHAR(18)  
QUESTIONNAIRE\_RETURNED\_DATE: CHAR(18)  
SMO\_RELATIONSHIP\_CD: CHAR(18)  
PRACTIVE\_TYPE\_CD: CHAR(18)  
PRIMARY\_IN\_OUT\_CD: CHAR(18)  
CRO\_NUM\_DAYS\_NOTICE: CHAR(18)  
PHASE1\_EXPERIENCE\_IND: CHAR(18)  
PHASE2\_EXPERIENCE\_IND: CHAR(18)  
PHASE3\_EXPERIENCE\_IND: CHAR(18)  
PHASE4\_EXPERIENCE\_IND: CHAR(18)  
PATIENT\_DATABASE\_IND: CHAR(18)  
SOFTWARE\_PACKAGE\_NAME: CHAR(18)  
CREATE\_DATE: CHAR(18)  
UPDATE\_DATE: CHAR(18)  
CREATE\_BY: CHAR(18)  
UPDATE\_BY: CHAR(18)

TO  
INV\_STAFF\_ROLE  
FIG. 22C

TO  
INV\_WORK\_LOCATION  
FIG. 22C

TO  
USER\_NOTES  
FIG. 22C

TO HMS\_INVESTIGATOR FIG. 22D

FIG. 22B

INV\_STUDY\_STAFF

91/114

FACILITY\_NAME: CHAR(18)  
STAFF\_ID: CHAR(18)

SOURCE\_CD: CHAR(18)  
FIRST\_NAME: CHAR(18)  
MIDDLE1\_NAME: CHAR(18)  
MIDDLE2\_NAME: CHAR(18)  
LAST\_NAME: CHAR(18)  
SUFFIX: CHAR(18)  
JOB\_TITLE\_CD: CHAR(18)  
WORK\_HOURS\_CD: CHAR(18)  
NUM\_YEARS\_RESEARCH\_EXP: CHAR(18)  
EMAIL: CHAR(18)  
PHONE\_NBR: CHAR(18)  
PHONE\_EXTENSION: CHAR(18)  
FAX\_NBR: CHAR(18)  
OFFICE\_MAIL\_STOP: CHAR(18)  
CREATE\_DATE: CHAR(18)  
UPDATE\_DATE: CHAR(18)  
CREATE\_BY: CHAR(18)  
UPDATE\_BY: CHAR(18)

2250

TO  
2252  
FIG. 22E

INV\_STAFF\_ROLE

INVESTIGATOR\_ID: CHAR(18)  
FACILITY\_NAME: CHAR(18)  
STAFF\_ID: CHAR(18)

SMO\_CONTACT\_IND: CHAR(18)  
OPPORTUNITY\_CONTACT\_IND: CHAR(18)  
CREATE\_DATE: CHAR(18)  
UPDATE\_DATE: CHAR(18)  
CREATE\_BY: CHAR(18)  
UPDATE\_BY: CHAR(18)

FROM  
2210  
FIG. 22B

INV\_WORK\_LOCATION

INVESTIGATOR\_ID: CHAR(18)  
FACILITY\_NAME: CHAR(18)

PRF\_IND: CHAR(18)  
DIRECT\_CONTACT\_IND: CHAR(18)  
CREATE\_DATE: CHAR(18)  
UPDATE\_DATE: CHAR(18)  
CREATE\_BY: CHAR(18)  
UPDATE\_BY: CHAR(18)

FROM  
2210  
FIG. 22B

TO  
2252  
FIG. 22E

USER\_NOTES

INVESTIGATOR\_ID: CHAR(18)  
USER\_NETWORK: CHAR(18)

NOTES: CHAR(18)  
CREATE\_DATE: CHAR(18)  
UPDATE\_DATE: CHAR(18)  
CREATE\_BY: CHAR(18)  
UPDATE\_BY: CHAR(18)

FROM  
2210  
FIG. 22B

FIG. 22C

92/114

FROM  
2210  
FIG. 22B

HMS\_INVESTIGATOR

CONTACT\_ID: NUMBER(7)  
INVESTIGATOR\_ID: CHAR(18)  
  
HMS\_ID: VARCHAR2(12)  
SOC\_SEC\_NBR: NUMBER(9)  
IND\_UPIN: VARCHAR2(7)  
FIRST\_NAME: VARCHAR2(25)  
MIDDLE\_NAME\_1: VARCHAR2(25)  
MIDDLE\_NAME\_2: VARCHAR2(25)  
LAST\_NAME: VARCHAR2(50)  
SUFFIX: VARCHAR2(10)  
CREDENTIAL: VARCHAR2(3)  
SEX: VARCHAR2(1)  
DOB: NUMBER(10)  
MED SCHOOL\_CD: VARCHAR2(8)  
GRADUATION\_YEAR: VARCHAR2(4)  
RSDNCY\_ORG: VARCHAR2(100)  
RSDNCY\_CITY: VARCHAR2(60)  
FLLWSHP\_ORG: VARCHAR2(100)  
FLLWSHP\_CITY: VARCHAR2(60)  
CREATION\_DATE: DATE  
UPDATE\_DATE: DATE  
CREDENTIAL\_2: VARCHAR2(3)  
INTRNSHP\_NAME: VARCHAR2(100)  
INTRNSHP\_CITY: VARCHAR(60)  
INTRNSHP\_STATE: VARCHAR2(2)  
UPIN\_SANC: VARCHAR2(50)  
STATE\_SANC: VARCHAR2(50)  
RSDNCY\_STATE: VARCHAR2(2)  
FLLWSHP\_STATE: VARCHAR2(2)

TO  
HMS\_HSPTL\_AFFLTN  
FIG. 22F

TO  
HMS\_SPECIALTY  
FIG. 22F

TO  
HMS\_DEA  
FIG. 22F

TO  
HMS\_BOARD\_CERT  
FIG. 22F

TO  
HMS\_LANGUAGE  
FIG. 22F

TO  
HMS\_INSURANCE\_AFFLTN  
FIG. 22G

TO  
HMS\_GRP\_UPIN  
FIG. 22G

TO  
HMS\_EMPLYR\_TAX\_ID  
FIG. 22G

TO  
HMS\_LICENSE  
FIG. 22G

TO  
HMS\_INV\_ADDRESS  
FIG. 22H

TO  
FDA\_1572  
FIG. 22H

FIG. 22D





FIG. 22E






FIG. 22G





FIG. 22H



## HMS\_HSPTL\_SVCS

CONTACT_ID: NUMBER(7)
HMS_HOSP_ID: VARCHAR2(9)
INVESTIGATOR_ID: CHAR(18)
AIDS_SVCS: VARCHAR2(1)
ANSTH_SVCS: VARCHAR2(1)
ANGPLSTY_SVCS: VARCHAR(1)
BLOODBKNK_SVCS: VARCHAR(1)
BMTRNSPL_SVCS: VARCHAR2(1)
BURNCTR_SVCS: VARCHAR2(1)
CRDCTH_SVCS: VARCHAR2(1)
CVSRGY_SVCS: VARCHAR2(1)
CHIRO_SVCS: VARCHAR2(1)
CLPSY_SVCS: VARCHAR2(1)
CT_SVCS: VARCHAR2(1)
DENTL_SVCS: VARCHAR2(1)
ULTRSND_SVCS: VARCHAR2(1)
DIETRTY_SVCS: VARCHAR2(1)
ECARD_SVCS: VARCHAR2(1)
ECONV_SVCS: VARCHAR2(1)
EMRGCY_SVCS: VARCHAR2(1)
ESWL_SVCS: VARCHAR2(1)
LABAN_SVCS: VARCHAR2(1)
HEART_SVCS: VARCHAR2(1)
HRTLUNG_SVCS: VARCHAR2(1)
HEMDIAL_SVCS: VARCHAR2(1)
HOMCRE_SVCS: VARCHAR2(1)
HOSPCE_SVCS: VARCHAR2(1)
CCU_SVCS: VARCHAR2(1)
ICU_SVCS: VARCHAR2(1)
KIDNEY_SVCS: VARCHAR2(1)
LABCLNC_SVCS: VARCHAR2(1)
LIVER_SVCS: VARCHAR2(1)
LUNG_SVCS: VARCHAR2(1)
MEGVRAD_SVCS: VARCHAR2(1)
NEONUNT_SVCS: VARCHAR2(1)
NICU_SVCS: VARCHAR2(1)
MRI_SVCS: VARCHAR2(1)
NEURO_SVCS: VARCHAR2(1)
NSURG_SVCS: VARCHAR2(1)
NUCMED_SVCS: VARCHAR2(1)
OBSRVA_SVCS: VARCHAR2(1)
OBSTE_SVCS: VARCHAR2(1)
OCCTH_SVCS: VARCHAR2(1)
OPNHT_SVCS: VARCHAR2(1)

FROM  
HMS\_HSPTL

FIG. 22I

TO FIG. 22K

FIG. 22J

HMS\_HSPTL\_SVCS (CONT'D)

FROM FIG. 22J

```
OPTOM_SVCS: VARCHAR2(1)
ORGANK_SVCS: VARCHAR2(1)
ORGAN_SVCS: VARCHAR2(1)
OUTPAT_SVCS: VARCHAR2(1)
OUTSRG_SVCS: VARCHAR2(1)
PANCR_SVCS: VARCHAR2(1)
PEDIAT_SVCS: VARCHAR2(1)
PHARM_SVCS: VARCHAR2(1)
PHYTH_SVCS: VARCHAR2(1)
PSTOP_SVCS: VARCHAR2(1)
PSYED_SVCS: VARCHAR2(1)
PULMON_SVCS: VARCHAR2(1)
RADIM_SVCS: VARCHAR2(1)
RECTH_SVCS: VARCHAR2(1)
REHAB_SVCS: VARCHAR2(1)
RESPIR_SVCS: VARCHAR2(1)
SELCARE_SVCS: VARCHAR2(1)
SKNLT_SVCS: VARCHAR2(1)
SOCSVC_SVCS: VARCHAR2(1)
SPEECH_SVCS: VARCHAR2(1)
THERD_SVCS: VARCHAR2(1)
TRAUMA_SVCS: VARCHAR2(1)
XRADT_SVCS: VARCHAR2(1)
CREATION_DATE: DATE
UPDATE_DATE: DATE
```

FIG. 22K




FIG. 22L




FIG. 22M




FIG. 22N




FIG. 220




FIG. 22P

105/114

Contact Information		Primary Research Facility		Study Staff		Trial Experience		Provider		Hospital		Prismatic View	
<b>Yellow = ABC Pharma Trial</b>													
Indication	Start Date	Enrollment Commitment	Evaluable Patients	Timeframe (months)	Enrollment Percentage	ABC Pharma Rank							
APT	1/15/2001	12	8	12	70%	4							
CHF	11/1/2000	10	9	9	90%								
CHF	10/5/2000	10	9	9	90%								
CHD	7/1/2000	8	3	6	40%								
CAD	6/1/1999	15	12	6	80%								
CHF	2/15/1999	8	7	10	90%								
CHF	3/1/1998	10	8	12	80%								
CHD	3/22/1997	6	4	10	60%								
CHD	6/1/1996	8	6	10	80%								

DATA SUPPLIED BY SPONSOR VIEWING SCREEN 2304

FIG. 23

NEWS\_XREF

106/114

2400




FIG. 24A




FIG. 24B




FIG. 24C

109/114

FROM  
THERAPEUTIC\_AREA  
FIG. 24A

RELATED\_SITE

TRPARA\_ID: NUMBER(12)  
WEBSITE\_ID: NUMBER(12)

WEBSITE

WEBSITE\_ID: NUMBER(12)  
ADDR\_ID: NUMBER(12)  
SHORT\_NAME: VARCHAR2(50)  
DISPLAY\_NAME: VARCHAR2(100)  
REFERAL\_SITE\_IND: VARCHAR2(5)  
URL: VARCHAR2(100)  
LAST\_UPD\_DT: DATE  
LAST\_UPD\_BY: VARCHAR2(30)

USER

USER\_ID: NUMBER(12)  
CMPY\_ID: NUMBER(12)  
ADDR\_ID: NUMBER(12)  
USERNAME: VARCHAR2(50)  
PASSWORD: VARCHAR2(50)  
EMAIL: VARCHAR2(100)  
HINT\_QUES: VARCHAR2(100)  
HINT\_ANS: VARCHAR2(100)  
LNAME: VARCHAR2(50)  
FNAME: VARCHAR2(50)  
MNAME: VARCHAR2(50)  
SEX\_CD: VARCHAR2(5)  
MYSELF\_FLAG: CHAR(1)  
ACTIVE\_FLAG: CHAR(1)  
INACTIVE\_DT: DATE  
PRF\_EMAIL\_FLAG: CHAR(1)  
PRF\_PHONE\_FLAG: CHAR(1)  
PRF\_MAIL\_FLAG: CHAR(1)  
CONTC\_TIME\_CD: VARCHAR2(5)  
TRAVEL\_CD: VARCHAR2(5)  
SHOW\_LIB\_FLAG: CHAR(1)  
SHOW\_PROF\_FLAG: CHAR(1)  
DESCR: VARCHAR2(2000)  
LAST\_UPD\_DT: DATE  
LAST\_UPD\_BY: VARCHAR2(30)  
ASK\_FLAG: CHAR(1)  
LAST\_NOTIF\_DT: DATE

FROM  
USER\_LIBRARY  
FIG. 24B

FROM  
USER\_ASK\_XREF  
FIG. 24A

FROM  
USER\_NOTIF\_PREF  
FIG. 24C

FROM  
USER\_SEARCH  
FIG. 24C

2420

TO

2410

FIG. 24E

TO  
USER\_TRIAL  
FIG. 24E

TO  
USER\_LOGIN\_POLICY  
FIG. 24E

TO  
USER\_REFERRAL  
FIG. 24E

FIG. 24D




FIG. 24E




FIG. 25




FIG. 26A

TO  
 - - - - -> INV\_INVESTIGATOR  
 FIG. 26B

113/114

INV\_INVESTIGATOR

INVESTIGATOR\_ID

SOURCE\_CD  
HMS\_ID  
FIRST\_NAME  
MIDDLE1  
MIDDLE2  
LAST\_NAME  
SUFFIX  
COUNTRY  
SOC\_SEC\_NBR  
IND\_UPIN  
SEX  
DOB  
MED SCHOOL\_CD  
GRADUATION\_YEAR  
RSDNCY\_ORG  
RSDNCY\_CITY  
FLLWSHP\_ORG  
FLLWSHP\_CITY  
DEGREE1  
DEGREE2  
PHONE\_NBR  
PHONE\_EXTENSION  
FAX\_NBR  
EMAIL  
CREDENTIAL  
DELETE\_REASON\_CD  
DELETE\_REQUEST\_DATE  
WRONG\_NUMBER\_IND  
CV RECEIVED\_DATE  
QUESTIONNAIRE\_RETURNED\_DATE  
SMO\_RELATIONSHIP\_CD  
PRACTIVE\_TYPE\_CD  
PRIMARY\_IN\_OUT\_CD  
CRO\_NUM\_DAYS\_NOTICE  
PHASE1\_EXPERIENCE\_IND  
PHASE2\_EXPERIENCE\_IND  
PHASE3\_EXPERIENCE\_IND  
PHASE4\_EXPERIENCE\_IND  
PATIENT\_DATABASE\_IND  
SOFTWARE\_PACKAGE\_NAME  
CREATE\_DATE  
UPDATE\_DATE  
CREATE\_BY  
UPDATE\_BY

FROM  
INV\_STUDY\_PERFORMANCE ----->  
FIG. 26A

FIG. 26B




FIG. 27